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ABSTRACT 
 
 
Protein aggregation is a major problem for biopharmaceuticals.  Aggregate 
formation in a drug formulation can have serious health implications for the patient.  
While the control of protein aggregation is critically important for the future of 
protein pharmaceuticals, the mechanism is still poorly understood.   In particular, the 
role that protein structure plays in aggregate assembly is not well understood.  We 
have selected the basic leucine zipper (bZIP) domain of activating transcription factor 
5 (ATF5) as model system with which to investigate the relationship between protein 
structure and aggregate assembly. This domain contains three regions with differing 
structural propensity: a disordered N-terminal polybasic region possessing transient 
helicity; a central, helical leucine zipper region; and a C-terminal, extended valine 
zipper region with a propensity to form beta structure. Additionally, a centrally 
positioned cysteine residue readily forms an intermolecular disulfide bond. We have 
modulated solution conditions and engineered mutations that affect the structure and 
aggregation of this domain in order to characterize how different structural elements 
participate in aggregate formation.  Specifically, we have evaluated the impact of 
intermolecular disulfide bond formation on ATF5 structure and stability.  We have 
also investigated how removal of the C-terminal valine zipper region affects ATF5 
structure and aggregation. 
Our results indicate that intermolecular disulfide bond formation facilitates the 
retention of helical structure and reduces the growth of thermally induced protein 
aggregates.  Additionally, the C-terminal valine zipper region is critical for the 
v 
v 
formation of α-helical structure.  Removal of this region results in a change in protein 
structure and a change in the mechanism of protein self-association.  The structure 
and stability of this truncated mutant are largely unaffected by intermolecular 
disulfide bond formation.  When compared to the wild-type ATF5 protein, this 
mutant displays increased self-association at low temperature but improved resistance 
to aggregate growth upon temperature elevation.  
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CHAPTER 1 
INTRODUCTION 
 
1.1 PROTEIN AGGREGATION 
 Achieving and maintaining product stability is a primary objective of the 
biopharmaceutical industry.1 Protein drugs are labile compounds in comparison to 
traditional, small molecule therapeutics.  Whereas the activity of small organic 
compounds is dependent solely on their chemical structure, proteins possess 
sophisticated higher order structure that must be maintained for activity.  Physical 
degradation of the native protein conformation can result in a loss of drug potency.  
Furthermore, physical degradation often leads to aggregation or non-native self-
association of protein molecules in solution.  Aggregation is a particular concern for 
drug products because it increases the likelihood that a patient will develop an 
undesired immune response.2  
 While preventing or at least controlling aggregate formation in 
pharmaceuticals is critically important, the mechanisms of assembly are not well 
understood.  Increasing evidence suggests that the structural features of partially 
folded intermediates play a key role in influencing aggregate assembly.3 The majority 
of structural information available regarding aggregate assembly comes from studies 
examining fibrillar protein aggregates. This type of protein aggregate has been 
heavily researched because of its involvement in numerous different disease states 
including Alzheimer’s disease (AD) and Parkinsons’s disease (PD).4 Fibrillar 
2 
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aggregates, also called amlyoids, are distinguished by a characteristic cross -beta-
sheet structure where the beta-sheet strands align in a highly organized format, 
perpendicular to the axis of the fibril.4a-c, 5 While the mechanism for formation of 
these beta-rich fibrils is not understood, several studies have reported the 
identification of a helical protein intermediate.6 These data suggest that a helix-to-
beta structural transition might be important in facilitating fibril formation.   
 Aggregate species that do not display long-range order have been termed 
amorphous protein aggregates.  Even though these aggregates lack long-range order 
they do possess structure and typically display a high beta-sheet content.7 The 
propensity of a protein system to form either amorphous or fibrillar protein 
aggregates in vitro is dependent not only upon the protein sequence and fold but on 
solution conditions.7a, b, 8 A number of proteins have been shown to selectively 
develop into either amyloid fibrils or amorphous aggregates depending on these 
conditions.8a, 9 A critical determinant in this selection is the nature of the unfolded or 
partially unfolded state.8a, 9 The structural features of the intermediate species present 
in pathways of amorphous aggregation are largely unknown, however it is clear that 
they play an important role in driving aggregate assembly.8a, 9   
 An important consideration when evaluating mechanisms of physical 
degradation is the relationship between protein chemical and physical structure.  
Numerous mechanisms for protein chemical degradation exist including deamidation, 
oxidation and disulfide scrambling.1a, b, 10 Any chemical modification to the protein 
molecule can affect the stability of the native structure or fold, possibly resulting in 
3 
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physical degradation.  These affects are quite protein-specific and heavily dependent 
upon the type and location of the chemical modification.  
 
1.2 ACTIVATING TRANSCRIPTION FACTOR 5 (ATF5) 
 Activating Transcription Factor 5 (ATF5) is a protein recognized for its 
importance in neural development and its contribution to brain cancer.11 The protein 
has been shown to maintain neural cells in a proliferative state and must be down 
regulated for differentiation to occur.11a, b ATF5 expression is not detected in mature 
neurons, but is present at high levels in developing neural tissue.11a, b Elevated levels 
of ATF5 have been observed in human brain cancer, specifically glioblastoma.11c, d 
Additionally, increased ATF5 expression is also detected in a number of human and 
rat glioma cell lines.11c The absence of detectable ATF5 in mature neurons, but 
elevated levels in cancerous tissue suggests that ATF5 may prove an ideal anticancer 
drug target.  An in vivo rat model demonstrated that interference with ATF5 
expression caused glioma cells to undergo apopotosis without affecting normal brain 
tissue.11c These data support the ideal that ATF5 is a promising target for anticancer 
drug treatment. 
 ATF5 was previously identified as a binding partner of a protein tyrosine 
phosphatase named Phosphatase of Regenerating Liver-1 (PRL-1).12 PRL-1 is the 
first isoform of the PRL family, which consists of three enzymes originally identified 
as up regulated during liver regeneration.13 14 High levels of PRL-1 expression are not 
just seen in regenerating liver but in many other tissues as well, including neural 
4 
4 
tissue.15 The interaction between PRL-1 and ATF5 has been mapped to the protein 
tyrosine phosphatase or active site domain of PRL-1 and the basic leucine zipper 
(bZIP) domain of ATF5.12 The biological significance of this interaction is unknown, 
however, increased levels of PRL-1 expression have been shown to induce cellular 
proliferation and tumor formation in several different systems.13-14 
 ATF5 belongs to the bZIP family of transcription factors, which are so named 
because all members possess a characteristic bZIP motif (Figure 1.1).  This motif 
consists of a basic region required for DNA binding followed by a leucine zipper 
region that facilitates protein dimerization.16 All members of the bZIP protein family 
function as dimers to bind DNA and regulate the process of transcription.  These 
proteins either homo- or hetero-dimerize selectively via stabilizing interactions 
between their leucine zipper domains resulting in the formation of a two-stranded 
coiled-coil.16 It is this dimerization between transcription factors that provides 
functional diversity and variable selectivity for DNA binding to the bZIP family.17 
 The leucine zipper motif consists of a repeating heptad unit (a-g), where the d-
position is almost exclusively occupied by leucine (Figure 1.2).18 The a-position is 
typically occupied by a hydrophobic or uncharged amino acid, while the e- and g-
positions are usually occupied by charged amino acids.  The a- and d-positions lie on 
one side of the alpha-helix and together comprise the hydrophobic interface of the 
coiled-coil.  The e- and g-positions are adjacent to the hydrophobic interface and 
facilitate electrostatic interactions that further stabilize coiled-coil formation.  A 
unique feature of the ATF5 protein is that three valine residues rather than leucine 
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occupy the d-positions at the C-terminal end of the leucine zipper doman.12, 19 The 
biological significance of this substitution is unknown, but it likely affects the 
selectivity, affinity and structure of ATF5 dimerization.     
 Currently no high-resolution structural data is available for ATF5.  A crystal 
structure has been reported for Activating Transcription Factor 4 (ATF4), a close 
homolog of ATF5 (Figure 1.3).20 ATF4 does not possess the extensive valine repeat 
present in ATF5, but the two proteins do share 74% sequence similarity.  ATF4 was 
reported to form a hetero-dimer with another bZIP protein, CCAAT Enhancer 
Binding Protein-β (CEBP-β).  In this structure ATF4 behaves as a rigid rod, while 
CEBP-β bends to wrap around ATF4 and form the coiled-coil.20 This behavior is 
unusual for a bZIP dimer, which typically consists of two monomers that both coil to 
wrap around each other.  While some evidence for ATF4 homo-dimerization exists, it 
seems unlikely for dimerization to be facilitated in the typical manner, suggesting that 
an alternative mechanism might be employed.20 Both ATF4 and ATF5 contain a 
cysteine residue in the a-position of the second heptad repeat of the zipper domain.  
While a number of other bZIP proteins possess cysteine residues within their zipper 
domain, only ATF4 and ATF5 possess a cysteine in this position.  It has previously 
been hypothesized that this cysteine might play a role in facilitating ATF4 
dimerization via disulfide bond formation, since it is positioned at the coiled-coil 
interface (Figure 1.4).20 The function of other transcription factors, including the 
Fos/Jun bZIP heterodimer, is regulated by disulfide bond formation.21 It is not known 
what effect disulfide bond formation has on ATF5 structure and function. 
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Figure 1.1 X-ray crystal structure of the GCN4 bZIP homodimer bound to DNA.19a 
DNA is shown in red.  Each bZIP monomer is shown in blue.  The leucine zipper 
domain comprised of the heptad repeat is depicted with the leucine residues shown in 
gray. 
 
 
   
 
Figure 1.2 A side and end-view schematic illustrating the packing arrangement of a 
two-stranded coiled-coil.19a The heptad repeat (a-d) is shown with arrows highlighting 
the electrostatic interactions between the e and g positions. 
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Figure 1.3 X-ray crystal structure of the ATF4-C/EBPβ heterodimer.20 The basic 
region of each protein is shown in red.  The fork region, which is a flexible region 
that connects the basic and leucine zipper domains, is shown in blue.  The leucine 
zipper domain is shown in white. 
 
 
Figure 1.4 Theoretical structure of an ATF4 homodimer containing an intermolecular 
disulfide via C310.20 
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1.3 ATF5 AS A MODEL SYSTEM OF PROTEIN AGGREGATION 
 Typically, model systems used for studying protein aggregation consist of 
amyloid-forming proteins or peptides.  The amorphous systems that have been 
investigated consist of molecules possessing sophisticated tertiary structure, often 
containing more than one intramolecular disulfide bond.22 This complexity makes a 
mechanistic interpretation of amorphous aggregation more difficult.  The bZIP 
domain of ATF5 possesses several characteristics that make it an interesting and 
unique model system for investigating amorphous protein aggregation.  The protein is 
helical in solution, but only partially folded and highly dynamic.23 This domain 
possesses only a single centrally-located cysteine residue that readily forms an 
intermolecular disulfide bond in solution and can be modulated by changing solution 
conditions.23 One side of the ATF5 helix consists of a hydrophobic interface that 
contains a leucine repeat following by a valine repeat.  An advantage of using ATF5 
as a model is the simplicity of its sequence and structure.  Single features affecting 
aggregation, such as helical content and disulfide cross-linking, can be modulated and 
evaluated individually.  Additionally, the effects of modification at the hydrophobic 
interface of the leucine zipper region can be investigated. 
 The analysis presented herein consists of the application of site-directed 
mutagenesis and the alteration of solution conditions to modulate ATF5 sequence and 
structure and evaluate the impact on protein aggregation. A variety of complementary 
biophysical techniques were utilized to characterize the structural features of ATF5 
and monitor the assembly of protein aggregates. The effects of intermolecular 
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disulfide bond formation and protein helicity on ATF5 structure and stability are 
presented in Chapter 3.  The effects of removal of the valine zipper region on ATF5 
structure and stability are presented in Chapter 4.  This investigation comprises a 
unique contribution to the study of protein aggregation by furthering our 
understanding of the relationship between structure and amorphous aggregate 
assembly using a novel protein system.    
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CHAPTER 2 
HIGH-YIELD EXPRESSION IN E. COLI AND REFOLDING OF THE BZIP 
DOMAIN OF ATF5 
 
2.1 INTRODUCTION 
 Activating Transcription Factor 5 (ATF5) recently has been recognized for its 
importance in neurological development and contribution to brain cancer. This 
protein functions to maintain the cell in a proliferative state and must be down 
regulated in order for differentiation to occur in neural progenitor cells 1.  While 
ATF5 is highly expressed in developing neurons, it is not expressed to any detectable 
level in healthy mature neural tissue 1a, 1c.  Increased levels of ATF5 have, however, 
been observed in primary brain tumors, and expression is elevated to particularly high 
levels in human glioblastoma 2.  It also is overproduced in several human and rat 
glioma cell lines 2.  The absence of ATF5 expression in mature neurons and its 
prominence in brain tumors has made it an appealing target for anti-cancer therapy.  
Importantly, an in vivo rat model has demonstrated that interference with ATF5 
function caused glioma cell death in primary tumors, while it did not affect the status 
of normal cells surrounding the tumor 2.  This data suggests ATF5 is a prime target 
for pharmaceutical intervention. 
 In general, there are two main approaches used to identify and develop lead 
pharmaceutical candidates.  The first relies on empirical testing of chemical 
compounds and requires a screening assay that is capable of quantifying the effect 
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compounds have on a given pharmaceutical target.  The second entails rational drug 
design, which is based upon high-resolution structural information about a 
pharmaceutical target.  The first step that must be taken to begin the analysis using 
either approach is production of the pharmaceutical protein target. In many cases 
involving multi-domain proteins, it is acceptable or advantageous to simplify the 
analysis by focusing the characterization specifically on the domain(s) that confer 
activity. In the case of ATF5, the portion responsible for DNA binding is of interest 
for assay development and structural characterization. ATF5 belongs to the bZIP 
family of transcriptions factors, which are composed of an unstructured N-terminal 
activating domain followed by a C-terminal bZIP domain 3.  The bZIP domain 
consists of a basic sequence that directly binds the DNA. The DNA binding sequence 
is followed by a helical leucine zipper region, which facilitates dimerization, 
increasing the DNA binding affinity 4.  The large, unstructured N-terminal domain 
typically is involved in more complex aspects of transcriptional regulation 3, 5.  The 
bZIP domain from numerous transcription factors has been shown to be amenable to 
structural characterization, and there are many instances where study of a bZIP 
protein has been performed using only this C-terminal domain 4. 
 The goal of the research described here was to produce the bZIP domain of 
ATF5 in sufficient yield and quantity to make high-resolution structure analysis and 
assay development feasible. We have developed a process to generate and maintain a 
soluble and stable solution of protein at sufficiently high concentration to permit such 
analyses.  This paper describes the procedure whereby the bZIP domain of ATF5 was 
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successfully expressed, purified and concentrated sufficiently to perform two-
dimensional NMR analysis. SDS-PAGE and mass spectrometry were used to confirm 
that we successfully produced and isolated the intact bZIP domain of ATF5.  The CD 
data indicate that ATF5 contains alpha helical content, showing that the protein 
obtained using our method has the expected secondary structure. 2D 1H-15N NMR 
data was acquired and the spectrum shows the protein is predominantly in the 
monomeric x-form state, indicating that structural analysis can be performed on 
ATF5 that has been produced using the method presented here 6. The functionality of 
ATF5 prepared under these conditions was confirmed using an electromobililty shift 
assay where the protein specifically bound to the cyclic AMP response element 
(CRE), which is a known DNA binding site of ATF5 7. 
 
2.2 MATERIALS AND METHODS 
2.2.1 Cloning and Construction of the Expression Plasmid 
 The cDNA of ATF5 was obtained through ATCC (MGC-842).  The portion 
encoding the bZIP domain was amplified using PCR for insertion to a plasmid using 
the following primers: 5’GCGCGCCCATGGGCCCTGCCACCACCCGA3’ 
(forward primer with NcoI restriction site), 
5’GCGCGCCATATGCCTGCCACCACCCGAGGG3’ 
(forward primer with NdeI restriction site), 
5’CGCGCGGGATCCTCAGCTACGGGTCCTCTG3’ (reverse primer with BamHI 
restriction site).  The amplified fragments were digested with the corresponding 
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endonucleases, gel purified and ligated into the pET-42b vector (Novagen) by 
overnight incubation with T4 Ligase at 16°C.  The NcoI site was used to insert the 
ATF5 gene following a Glutathione-S-Transferase (GST) tag, whereas insertion at the 
NdeI site generated a construct from which untagged ATF5 could be expressed.  The 
ligation product was transformed into competent Novablue E. coli (Novagen) using 
the standard heat shock protocol.  Transformed colonies were grown overnight at 
37°C on LB agar plates containing 30 µg/ml kanamycin.  Individual colonies were 
selected and used to inoculate 5 ml M9ZB containing 0.4% glucose, 1 mM MgSO4 
and 30 µg/ml kanamycin.  Cultures were incubated with shaking overnight at 37°C.  
Plasmid DNA was isolated from the overnight cultures using a Qiagen miniprep kit.  
Purified DNA was verified to be correct by bidirectional sequencing (Northwoods 
DNA). 
2.2.2 Protein expression 
 BL21(DE3) E. coli (Novagen) were transformed with the pET-42b-ATF5 
bZIP plasmid using the standard heat shock protocol. Transformed colonies were 
selected and grown overnight at 37°C on LB agar plates containing 30 µg/mL 
kanamycin.  Colonies were selected and used to inoculate 5 mL LB containing 0.4% 
glucose, 1 mM MgSO4, and 30 µg/mL kanamycin.  Cultures were grown with 
shaking overnight at 37°C.  Two starter cultures were used to inoculate one 500 ml 
culture containing minimal media consisting of deionized water supplemented with 
0.1% ammonium chloride, 1% glucose, 10 mM MgCl, 40 µg/mL thiamine HCl, 30 
µg/mL kanamycin plus additional salts (100 mM KH2PO4, 57 mM K2HPO4, 63 mM 
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Na2HPO4, 14 mM K2SO4) and trace minerals (200 µM CaCl2•H2O, 100 µM 
FeSO4•H2O, 50 µM MnCl2•6H2O, 15 µM CoCl2•6H20, 10 µM ZnSO4•7H2O, 9 µM 
CuCl2•2H2O, 1.5 µM H3BO4, 1.2 µM (NH4)Mo7O24•4H2O, 65 µM Na2EDTA).  
Isotopic labeling was accomplished via substitution with 15N-labeled ammonium 
chloride (Spectra Isotopes).  Cultures were grown to an OD550 of 0.6 to 0.8 before 
inducing protein expression with a final concentration of 1 mM isopropyl-β-D-
thiogalactopyranoside (IPTG).  Cells were incubated with shaking at 37°C for 4 
additional hours post induction, harvested by centrifugation at 3000 x g and stored at 
-80°C. 
2.2.3 Purification of the GST-tagged ATF5 construct 
 Cell pellets were thawed on ice and resuspended in cold phosphate buffered 
saline (PBS), pH 7.3 (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4) containing 5 mM dithiothreitol (DTT).  Each pellet derived from 1 L culture 
was taken up in 25 mL solution and lysed via passage through a french pressure cell.  
Lysates were centrifuged for 1 hour at 21,000 x g and 4°C.  The supernatant was 
decanted and passed through a 0.2 µm filter.  The filtrate was loaded onto a 5 mL 
GSTrap column (GE Healthcare) at a flow rate of 1 mL/min.  The column was rinsed 
with 10 column volumes (CV) of loading buffer or PBS, pH 7.3 containing 5 mM 
DTT at 3 mL/min.  Elution was performed with 3 CV of elution buffer or 50 mM Tris 
HCl, pH 8.0 containing 10 mM reduced glutathione (GSH) and 5 mM DTT at 3 
mL/min.  Chromatographic separation was carried out at 4-8°C.  Fractions were 
collected and stored cold prior to analysis by SDS-PAGE. 
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 Eluted fractions containing ATF5 were concentrated by ultrafiltration using a 
3500 MWCO Millipore ultrafilter with a Biomax membrane and centrifuged at 4000 
x g and 4°C.  Subsequently, Factor Xa (Novagen) was added to each sample at a 
concentration of 10 units/mL and incubated overnight (approximately 16 hours) at 
room temperature to cleave the GST tag.  Cleavage progress was monitored by SDS-
PAGE.  The GST tag was removed by incubating the cleaved protein with 
glutathione-agarose beads (BD Biosciences) for 30 minutes at room temperature.  The 
sample was centrifuged at 16,000 x g for 10 minutes to pellet the agarose beads and 
recover the ATF5 protein.  
2.2.4 Protein extraction and refolding 
 Cell pellets were thawed, resuspended in PBS, pH 7.3 containing 5 mM DTT 
and lysed as described above.  The insoluble pellet was resuspended by vortexing it in 
4 mL of 50 mM sodium phosphate, pH 6.5 containing 100 mM NaCl, 6 M guanidine 
HCl and 5 mM DTT.  The solution was incubated at room temperature for 3 hours to 
permit denaturation to occur before separating the soluble and insoluble material by 
centrifugation for 1 hour at 21,000 x g and 4°C.  The solubilized protein was refolded 
by dilution into 40 mL of 50 mM sodium phosphate, pH 6.5 containing 100 mM 
NaCl and 5 mM DTT 8.  Insoluble components were pelleted by centrifugation for 1 
hour at 21,000 x g and 4°C.  The supernatant containing refolded ATF5 was dialyzed 
using 1000 MWCO dialysis tubing with a cellulose membrane (Spectra) overnight at 
4°C into 2 L of phosphate buffer (50 mM sodium phosphate, pH 6.5, 100 mM NaCl, 
5mM DTT) to remove the guandinium.  The ratio of protein to dialysis solution was 
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0.04 L protein: 2 L dialysis buffer, which results in a 50-fold dilution of guanidinium 
to a final concentration of 12 mM.  Any precipitation generated during dialysis was 
removed by centrifugation for 1 hour at 21,000 x g and 4°C.  The supernatant 
containing soluble protein was collected and concentrated using a 15 mL 3500 
MWCO Millipore ultrafilter with a Biomax membrane and exchanged into the same 
buffer solution (50 mM sodium phosphate, pH 6.5, 100 mM NaCl) without DTT.  
The solution was concentrated to approximately 1 mL and then exchanged into 20-
fold excess buffer to further remove guanidinium, reducing the final concentration to 
less than 1 mM.  Sample purity was assessed by SDS-PAGE analysis. 
2.2.5 Denaturing Gel Electrophoresis 
 SDS-PAGE was performed according to the Laemmli procedure 9.  GST-
tagged ATF5 was separated on a discontinuous system consisting of a 5% (v/v) 
stacking gel and a 12% (v/v) resolving gel, whereas untagged ATF5 was resolved 
using a 15% (v/v) gel.  Samples were diluted with 2x Laemmli buffer and heated at 
90°C for 10 minutes before being loaded onto the gel.  To examine the presence of 
disulfide-linked species a non-reducing loading buffer was used, which did not 
contain any reducing agent.  An unstained molecular weight marker was used for 
reference (Bio-Rad Precision Plus standards).  Coomassie staining was performed to 
visualize protein content.  
 
21 
21 
Densitometry was perfomed on Coomassie stained SDS-PAGE gels using a Typhoon 
Trio Variabel Mode Imager (Amersham Biosciences) and the amount of protein in 
each band was determined using ImageQuant TL software (Amersham Biosciences).   
2.2.6 Protein Concentration Determination 
 The molar concentration of the purified ATF5 solution was determined using 
the Beer-Lambert Law (A=εlc).  A theoretical molar absorptivity value (ε) 
corresponding to 280 nm was calculated to be 4470 M-1cm-1 using the Expasy 
Proteomics Server 10.  A280  absorption readings were measured in a 1 cm, quartz 
cuvette using a Cary 100 UV-Visible spectrophotometer. 
2.2.7 Liquid Chromatography and Mass Spectrometry 
 Non-reduced samples of ATF5 were prepared at a concentration of 0.2 mM in 
100 mM ammonium bicarbonate buffer, pH 6.0.  In order to prepare reduced samples, 
5 mM DTT was added to the non-reduced stock and the solution was heated at 37°C 
for 20 minutes prior to injection on the column.  Microbore HPLC/MS experiments 
were performed to determine the mass of the ATF5 product and investigate the 
existence of intermolecular disulfide bonds.  The HPLC step was used to desalt and 
separate proteins chromatographically (Waters Acquity).  Solvents A and B contained 
99% H2O, 1% CH3CN and 99% CH3CN, 1% H2O, respectively, and both contained 
0.08% formic acid.  Separations were performed on a 1 mm ID x 5 cm long C4 
reverse phase column (Vydac C4, 300Å pore size, 3.5 µM particles packed 
by MicroTech Scientific, Vista, CA) at 110 µl/min.  The gradient was held at 1% 
B for 3 min, then ramped to 23% B by 4 min, 45% by 14 min, and 90% B by 15 min.  
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Partial resolution of the ATF5 monomer from dimer in the non-reduced sample was 
observed near 28 % B with this gradient. 
 Electrospray ionization (ESI) spectra were acquired on a Q-Tof-2 (Micromass 
Ltd, Manchester UK) hybrid mass spectrometer operated in MS mode and acquiring 
data with the time of flight analyzer.  The instrument was operated with analyzer 
settings optimized for maximum sensitivity while infusing a 50% organic/water 
solution of lysozyme at the flow rate of the chromatography.  The cone and collision 
cell voltages (35 and 20V, respectively) were a compromise to maximize sensitivity 
and keep the M-H2O/NH3 ion below 20% of the primary ion in each charge state 
cluster.  Argon was admitted to the collision cell using 16 psi on the supply regulator 
or 5.3 x 10-5 mBar on a penning gauge near the collision cell.  Spectra were acquired 
at an 11,364 Hz pusher frequency, covering the mass range 800 to 3000 u and 
accumulating data for 5 seconds per cycle.  Time to mass calibration was made with 
CsI cluster ions acquired under the same conditions. The resulting suite of charge 
states in the ESI spectrum were subject to charge state deconvolution to present a 
“zero” charge mass spectrum using the Transform or MaxEnt1 routine in MassLynx 
software. 
2.2.8 NMR Spectroscopy 
 Two-dimensional 1H-15N heteronuclear single quantum coherence (HSQC) 
spectra were recorded at 25°C using a Bruker AVANCE 800 MHz spectrometer 
equipped with a triple-resonance CRYO-probe with pulse field gradients. Samples 
were prepared at a concentration of 0.2 mM in 50 mM sodium phosphate, pH 6.5, 
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containing 100 mM NaCl, 5 mM DTT and 5% D2O.  Water suppression was 
accomplished using flip-back pulses. Data were acquired in 128 scans with 2048 
points in 1H and 128* increments in 15N. 1H chemical shifts were referenced with 
respect to an external DSS standard in D2O 11.  Indirect referencing relative to 1H was 
determined for 15N, assuming a ratio of 15N/1H = 0.101329118 11.  Data were 
processed using NMRPipe and Sparky software 12.  
2.2.9 Circular Dichroism Spectroscopy 
 Data were collected on a Jasco J-720 spectrapolarimeter equipped with a 
Peltier temperature control unit.  Samples consisted of 20 µM protein in 50 mM 
sodium phosphate buffer, pH 6.5, and 100 mM NaCl.  Spectra were acquired at 10°C 
using a quartz cuvette with a 1 mm path length.  Scans were collected in the range of 
190 to 260 nm, a data pitch of 1 nm, a band width of 5 nm, a scanning speed of 50 
nm/min and a response time of 8 seconds. Sample spectra were corrected by 
subtraction of the buffer spectrum, and molar ellipticity was calculated using a 
molecular weight of 9.33 kDa.  
2.2.10 Electromobility Shift Assay 
 The DNA binding activity of the bZIP domain of ATF5 was determined using 
a 20 base-pair, double-stranded oligonucleotide probe containing the cyclic AMP 
response element (CRE) binding motif (5′-TAAAAATGACGTCATGGTAA-3′). The 
forward primer was modified at its 5’ end with a 6FAM fluorescent tag for detection 
(IDT). The forward and reverse strands were preannealed to generate double-stranded 
DNA by heating at 90°C for 5 minutes before cooling to room temperature over the 
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next 11 minutes.  A 2 µL volume of a 1 mM stock of purified ATF5 was combined 
with 2 µL of a 1 µM stock CRE DNA containing the fluorescent tag in 12 µL of 
binding buffer (10 mM Tris, pH 7.5, 50 mM NaCl, 1 mM EDTA 1 mM DTT, 5 mM 
MgCl2, 10% (v/v) glycerol) and incubated at room temperature for 15 minutes. As a 
control, 100-fold excess of preannealed unlabeled CRE DNA was added to ATF5 as a 
competitive inhibitor in the above reaction. After the addition of loading buffer, 10 
µL of each sample was loaded onto a 20% nondenaturing polyacrylamide gel.  The 
gel was run at 100 V for one hour and the 6FAM-labeled DNA was detected using a 
Typhoon Trio Variable Mode Imager (Amersham Biosciences).  Excitation of the 
fluorophore was done at a wavelength of 488 nm and emission was detected at 520 
nm.  
 
2.3 RESULTS 
2.3.1 Expression and purification of GST-tagged ATF5 
 The initial attempt to obtain the bZIP domain of ATF5 involved production of 
it in a fusion construct with a N-terminal GST-tag, as previously reported 7.  SDS-
PAGE analysis of pre- and post-induction samples demonstrated successful 
expression of this protein, as detected by the presence of a band at 38 kDa, which is 
the expected molecular weight for this construct (Figure 2.1A).  Although the 
majority of recombinant protein was insoluble following cell lysis (Figure 1B, lane 
9), we isolated the soluble fraction (lane 1) by centrifugation, which contained 
approximately 9 mg GST-ATF5.  Affinity chromatography then was performed on 
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the soluble fraction using a GSTrap column. Isolation of the fusion construct from 
other soluble proteins was achieved using this method; however, extensive secondary 
proteolysis occurred during the purification. The initial cell lysate contained a 38 kDa 
band (Figure 2.1B, lane 1), which corresponds to the full-length fusion protein, 
whereas the eluate (lane 5) lacked this band and instead contained a band at 
approximately 35 kDa. Based on the change in molecular weight of these observed 
bands, proteolytic cleavage does not correspond to release of the 10 kDa ATF5 bZIP 
protein. Subsequent attempts to specifically cleave the GST tag from ATF5 using 
Factor Xa were unfruitful, as demonstrated by the lack of a band near the expected 
molecular weight for the full-length ATF5 bZIP domain or a partially cleaved 7 kDa 
fragment (Figure 2.1B, lane 7).  Moreover, the intensity of the band at 35 kDa did not 
decrease to an appreciable extent following incubation with Factor Xa (Figure 2.1B, 
lane 7), suggesting that access to the cleavage motif may be blocked. After 
completing the chromatographic separation, the GSTrap resin was washed with 1% 
SDS to remove any residual proteins from the column. This fraction contained a large 
amount of GST-ATF5 (Figure 2.1B, lane 8), which suggests the protein had 
aggregated on the column or formed large oligomers that were not effectively 
competed off the resin during the elution step.  
 Most of the expressed fusion protein was located in the insoluble cellular 
fraction (Figure 2.1B, lane 9), suggesting that the ATF5 bZIP protein may be poorly 
soluble or prone to aggregation.  Aggregate formation in solution also could limit 
access to the Factor Xa cleavage site, resulting in retention of the apparent higher 
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molecular weight bands.  Because much of the GST-tagged ATF5 was insoluble 
following cell lysis and efforts to cleave the tag from the soluble protein were 
unsuccessful, an alternative approach was devised to obtain ATF5.  Because GST 
(not fused to ATF5) is present in the soluble portion of the cell lysate, we expected 
that untagged ATF5 would appear in the pellet. Many proteins that are directed to 
inclusion bodies can be recovered from the insoluble pellet using a denaturation and 
refolding procedure 8.  We decided to investigate whether improved yields of the 
ATF5 bZIP protein could be achieved by purifying an untagged version from this 
insoluble fraction. 
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Figure 2.1 (a) Coomassie stained SDS-PAGE showing expression of GST-ATF5 
bZIP.  Lane 1: E.Coli lysate pre-IPTG induction, Lane 2: E.Coli lysate post-IPTG 
induction, Lane 3: molecular weight marker (Bio-Rad Precision Plus Unstained MW 
Standard).  (b) Coomassie stained SDS-PAGE gel showing fractions from the 
purification of GST-ATF5 bZIP using GSTrap affinity chromatography. Lane 1: 
supernatant following cell lysis, Lane 2: column flow-through, Lane 3: rinse fraction, 
Lane 4:  elution fraction #1, Lane 5: elution fraction #2, Lane 6: elution fraction #3, 
Lane 7: Eluate after dialysis, reaction with Factor Xa and incubation with GSTrap 
beads, Lane 8: GSTrap beads containing residual protein post GST removal, Fraction 
9: insoluble pellet after cell lysis, Fraction 10: molecular weight marker (Bio-Rad 
Precision Plus Unstained MW Standard). 
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2.3.2 Expression and refolding of untagged ATF5  
 Analysis of the SDS-PAGE data revealed that a high level of expression of the 
untagged form of ATF5 was achieved from this construct (Figure 2.2A).  Anomalous 
behavior was observed for this protein when evaluated using SDS-PAGE analysis.  
The protein runs more slowly than would be expected, likely due to its basicity and 
overall highly positive charge (pI=10.07).  This behavior has been observed with 
ATF5 before and with other highly basic proteins 7, 13.  To confirm the band at 
approximately 12 kDa corresponds to ATF5, mass spectrometric data was collected 
(Figure 2.3).  The MS spectrum shows a peak at 9333.7 u, which provides 
confirmation that the product obtained has the expected mass calculated for ATF5 
bZIP (9333.4 Da). 
 The cells containing untagged ATF5 were lysed and centrifuged using the 
same conditions and procedure as described above. SDS-PAGE revealed that the 
majority of ATF5 protein is contained in the pellet following lysis.  ATF5 was 
extracted efficiently from the insoluble pellet when incubated with a high 
concentration of the denaturant guanidine and the reducing agent DTT (data not 
shown). The protein refolded as the denatured solution was diluted drop wise into a 
large volume of non-denaturing buffer. Samples from each step in the purification 
process could not be analyzed by SDS-PAGE, because this method in incompatible 
with the use of guanidine HCl.  There was some precipitation or turbidity observed 
during the refolding step, which could be due to the presence of lipids and/or 
membrane proteins that did not refold upon dilution.  This insoluble material was 
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successfully pelleted by centrifugation following refolding, and the clarified 
supernatant was decanted and dialyzed. The dialysis step, which facilitated a 50-fold 
reduction in the guanidine concentration, resulted in some visible precipitation.  The 
precipitate was removed by centrifugation prior to concentration of the final material.  
Initial attempts at refolding were conducted in Tris buffer at pH 7.5.  Under these 
solutions conditions, the protein was found to be highly prone to aggregation as 
detected by visual observation of large amounts of precipitation.  Performing the 
refolding step in phosphate buffer at pH 6.5, however, allowed for greater protein 
stability and increased solution concentrations to be achieved. 
Using phosphate buffer, our scheme for obtaining untagged ATF5 from the 
insoluble cellular fraction yielded approximately 8 mg protein from a 1 L culture, as 
determined by an A280 absorption reading (Table 2.1).  Densitometry was performed 
to quantify the total amount of ATF5 produced and the percent purity of the final 
product (Figure 2.2B).  Approximately 45 mg of total protein were present in the 
whole cell lysate derived from 1 L culture, and 20% (or 9 mg) of this corresponds to 
ATF5 bZIP (Table 2.1).  The final yield of purified ATF5 bZIP was 8 mg, which in 
relation to the total amount produced is 89%.  This methodology not only allowed for 
a very high yield of purified product, but using these conditions concentrations of 
ATF5 in excess of 0.2 mM (or 2 mg/mL) could be achieved, which permits study of 
the protein using multi-dimensional NMR analysis.   
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Figure 2.2 (a) Coomassie stained SDS-PAGE showing expression of ATF5 bZIP. 
Lane 1: E.Coli lysate pre-IPTG induction, Lane 2: E.Coli lysate post-IPTG induction, 
Lane 3: molecular weight marker (Bio-Rad Precision Plus Unstained MW Standard).  
(b) Coomassie stained SDS-PAGE gel showing lysis fractions and purified ATF5 
bZIP.  Lane 1: molecular weight marker (Bio-Rad Precision Plus Unstained MW 
Standard), Lane 2: whole cell lysate, Lane 3: insoluble pellet after lysis, Lane 4: lysis 
supernatant, Lane 5: purified ATF5 bZIP domain. 
 
 
 
 
 
Table 2.1 ATF5 expression and final yield.
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2.3.3 Mass Spectrometric Analyses 
 Analysis of a non-reduced sample of ATF5 indicated the presence of both 
monomeric (average theoretical mass = 9333.4) and covalently-linked dimeric 
(average theoretical mass = 16664.8) species (Figure 2.3A).  Reduction of ATF5 by 
DTT resulted in loss of signal from the dimer and a concomitant increase in signal 
from the monomer (Figure 2.3B).  SDS-PAGE performed in the absence of DTT or 
any reducing agent further confirmed the presence of a mixture of monomeric and 
dimeric species in the refolded ATF5 sample (Figure 2.3C).  Addition of DTT to the 
sample followed by SDS-PAGE produced a single band corresponding exclusively to 
the monomer.  The apparent molecular weight of the dimer is 24 kDa, which is 
consistent with the migration of the monomeric species at approximately 12 kDa.  
The SDS-PAGE results indicate an intermolecular disulfide bond forms readily in 
solution.  Densitometry performed on the SDS-PAGE gel shown in Figure 3 reveals a 
ratio of 1.0:1.7 monomer:dimer. 
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Figure 2.3 (a) Transformed mass spectrum of non-reduced ATF5 bZIP domain. (b) 
Transformed mass spectrum of reduced ATF5 bZIP domain. (c) Coomassie stained 
SDS-PAGE gel of purified ATF5 bZIP. Lane 1: molecular weight marker (Bio-Rad 
Precision Plus Unstained MW Standard), Lane 2: reduced sample of ATF5, Lane 3: 
Non-reduced sample of ATF5. Note: The non-reduced sample was run on the same 
gel as the reduced sample but with several lanes in between the two to prevent 
diffusion of the reducing agent into the non-reduced lane. The intermediate lanes 
were removed from the figure above and the two sample lanes were placed adjacent 
one another to allow for better comparison. 
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2.3.4 NMR Analysis 
 Purified 15N-labeled ATF5 bZIP was examined using two-dimensional, 
heteronuclear NMR to verify that the protein can be detected by the spectrometer and 
is not aggregated when prepared at high concentration, as this would impede further 
structural investigations using solution NMR.  A spectrum of the reduced ATF5 
sample was acquired using the 15N-HSQC experiment, because further evaluation of 
protein structure using NMR often relies on HSQC-based experiments. The 15N-
HSQC selectively detects NH pairs and correlates each 1H to the directly attached 
15N. This spectrum is considered a “fingerprint” of the protein, because chemical 
shifts reflect the unique environment encountered by each nucleus in the backbone in 
an organized structure. A well-behaved globular protein will have good signal 
dispersion, typically ranging from 6 to 12 ppm on the 1H axis and 100 to 140 ppm on 
the 15N.  This dispersion results from the presence of stable structural features that 
confine the amide groups of the constituent amino acids to unique chemical 
environments within the folded protein. As such, more disordered proteins typically 
have peaks clustered more closely around random coil values (~8.3 ppm in 1H), 
because on average the nuclei experience more similar chemical environments in 
solution than in the structured protein 14.  The HSQC spectra of proteins composed of 
only a single helix, like the ATF5 bZIP monomer, are difficult to interpret without 
additional data, because in a standard alpha helix, all the amides are in similar 
environments. Their environment, however, can be altered upon dimerization, and the 
presence of peaks in more unusual positions can imply coiled-coil formation 6, 15. 
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 The 1H-15N HSQC spectrum of reduced ATF5 suggests that the protein is 
predominantly in a monomeric, homogeneous state under the conditions used (Figure 
2.4). Limited chemical shift dispersion is observed in the spectrum, as the majority of 
peaks appear between 7.9 and 8.5 ppm on the 1H axis (see black peaks in Figure 2.4). 
The narrow range of peak positions is consistent with the presence of a species that is 
composed of a single helix and/or is unstructured 14.  Side chain NH2 moieties from 
Asn and Gln residues produce a pair of 1H peaks corresponding to a single 15N value, 
which are observed at approximately 112 ppm. In the spectrum of ATF5, all the side 
chain amides have nearly equivalent chemical shifts to each other and the free amino 
acids, suggesting all are equally solution exposed. While this single NMR spectrum 
of ATF5 cannot be used to distinguish regions of α-helix from random coil, it does 
indicate that the protein exists largely in a homogeneous state. Increased signal 
dispersion is, however, observed closer to the noise (see red peaks in Figure 2.4).  
The peaks highlighted in red are visible only at a 10-fold lower signal-to-noise ratio 
than the peaks shown in black.  The red peaks near 111 ppm on the 15N axis and also 
those at larger 15N values between 8.3 and 7.4 ppm on the 1H axis are characteristic of 
higher order structure. Among these peaks is a pair that corresponds to an NH2 side 
chain (111.1 ppm 15N, 6.75 and 7.46 ppm 1H). The presence of these peaks indicates 
that the environment around one of the Asn or Gln side chains is altered in the more 
structured state by participating in a protein-protein interaction. Overall, the red peaks 
constitute only a small percentage of the total peak intensity (less than 10%) in the 
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ATF5 spectrum, suggesting that even at 0.2 mM concentration a minimal amount of 
higher-order structure is present. 
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Figure 2.4 2D 1H-15N HSQC spectrum of 0.2 mM 15N-labeled ATF5 in 50 mM 
sodium phosphate, pH 6.5, containing 100 mM NaCl and 5 mM DTT.  Peaks in black 
are observed at S/N ratio = 1000:1.  Peaks in red were overlaid onto the spectrum in 
black and are observed only at signal/noise ratio = 100:1. 
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2.3.5 Circular Dichroism Analysis 
 CD was performed on ATF5 bZIP to determine the secondary structure.  
Analysis of the CD spectrum of the purified bZIP domain of ATF5 shows the 
presence of α-helical structure, evident in the double minima absorption observed at 
both 208 and 222 nm (Figure 2.5).  CD data can be used to quantify the relative 
amounts of secondary structure in a protein.  A simple calculation using the following 
equation can be performed to estimate the α-helical content: 
[θ]222 = -30,300fH – 2340, 
where [θ]222 is the mean residue ellipticity at 222nm and fH is the fraction of α-helical 
content in the protein 16.  This equation has been applied to other bZIP domains as a 
means of approximating the percent of alpha helix composing the structure 17.  Using 
this method, the calculated percent helix in ATF5 bZIP is 27%. The estimate equates 
to the involvement of 21 residues per monomer in helical structure. A more accurate 
quantitative analysis requires the inclusion of the data from 190 to 260 nm. 
Absorption data for this entire range could not be obtained for ATF5. Data between 
190 and 200 nm is not shown because measurement in this region is unreliable under 
the conditions required for ATF5 analysis.  Absorption from buffer components 
interferes with the data collection, and rigorous quantitative analysis cannot be 
performed because signal from the ATF5 protein cannot be deconvoluted.  
2.3.6 DNA Binding Analysis 
The DNA binding activity of ATF5 was examined using an electromobility 
shift assay (Figure 2.6). Because it was previously reported that ATF5 binds to the 
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CRE motif, we incubated the purified bZIP domain with fluorescently labeled double-
stranded oligonucleotide DNA containing this motif to verify the protein functions as 
expected 7.  A shift in the electrophoretic mobility of the CRE DNA is observed in the 
presence of ATF5. As expected the DNA: protein complex migrates more slowly 
(Figure 2.6, lane 2) than that of the DNA alone (lane 1). Addition of 100-fold excess 
unlabeled CRE DNA results in restoration of the band corresponding to unbound 
labeled CRE (lane 3). This indicates that binding is reversible because unlabeled CRE 
effectively competes with labeled CRE for ATF5 binding.      
39 
39 
 
 
Figure 2.5 Circular dichroism absorption spectrum of the bZIP domain of ATF5 at 20 
µM concentration in 50 mM sodium phosphate, pH 6.5, containing 100 mM NaCl 
and 5 mM DTT.  The double minimum at 208 and 222 nm indicates α-helix is present 
in ATF5. 
 
 
 
 
Figure 2.6 Native PAGE showing the electrophoretic mobility of fluorescently 
tagged CRE DNA in the absence and presence of ATF5. Lane 1: dsCRE DNA, Lane 
2: dsCRE DNA in the presence of ATF5, Lane 3: dsCRE DNA in the presence of 
ATF5 and 100-fold molar excess of unlabeled dsCRE DNA. 
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2.4 DISCUSSION 
 The results presented here show for the first time that the bZIP domain of 
ATF5 can be expressed and purified in sufficient quantity, concentration and 
homogeneity to facilitate assay development and structural analyses.  Our refolding 
procedure for isolating ATF5 is simple and involves limited introduction of surfaces 
that could initiate aggregation or adsorption events, which is important because the 
protein appears prone to aggregation. The procedure is efficient, resulting in a very 
high yield of soluble protein in which the final product is sufficiently pure to permit 
spectroscopic or structural analysis.  
 Most reports of bZIP proteins indicate that these domains are unstructured or 
weakly helical and monomeric in solution and their helicity is stabilized by DNA 
binding via coiled-coil formation. An exception to this was reported in two separate 
studies on GCN4 that provided evidence that monomeric and dimeric species can be 
helical in solution and both are able to bind DNA 18. Our data most closely resembles 
that of GCN4. The CD results for reduced ATF5 indicate approximately one-third of 
the bZIP domain is alpha helical in solution in the absence of DNA, while the NMR 
spectrum lacks the dispersion typically associated with coiled-coil formation. In the 
expressed protein, approximately 45% of the sequence constitutes the basic DNA 
binding segment while the other 55% is expected to compose the leucine zipper. The 
DNA binding region is expected to be in a random coil conformation in the absence 
of DNA. The remaining residues typically are helical in the coiled-coil form, which 
equates to 43 residues in our construct. Our CD data shows that approximately half of 
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the predicted zipper region (21 residues) is helical in solution. The comparatively low 
helical content likely results because the last two typically conserved Leu positions in 
the zipper region are occupied by valine residues in ATF5. Approximately 90% of the 
peaks in the NMR spectrum (black in Figure 4) are within a narrow range, which is 
consistent with the presence of a monomer. If ATF5 exists predominantly as a coiled-
coil dimer, the chemical shifts in the NMR spectrum would be expected to appear in a 
broader range than is observed. The fact that the NMR data was acquired at a 10-fold 
greater protein concentration negates the possibility that there is any coiled-coil in the 
CD sample and indicates that the monomer is helical. The subset of more disbursed 
peaks in the NMR spectrum, which have weaker intensity, suggest that only a minor 
amount of homodimer is present at the higher protein concentration. An additional 
recent study of GCN4 provides good evidence to support this conclusion, as it 
identified the presence of an intermediate form of the GCN4 protein (x-form) that is 
monomeric yet retains helical structure in the absence of DNA 6.  This study further 
describes a subset of more distributed NMR peaks, which reflect the coiled-coil 
structure.  The black peaks in our spectrum of ATF5 are consistent with ATF5 being 
in the x-form, while the red peaks resemble those observed for the coiled-coil form in 
the GCN4 study. The pair of NH2 peaks shown in red further lends support to the idea 
that these peaks reflect dimer formation, because in other bZIP domains a conserved 
Asn is embedded in the dimer interface 4d.  This residue is in the a position in the 
helix, which directly participates in the “knob and hole” packing arrangement 
composing the coiled-coil 19.  It is most likely that the shifted NH2 peaks correspond 
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to the analogous position in ATF5, which is occupied by Asn245.  Peak assignment 
and structure determination will be required to test this hypothesis.  
 The bZIP family proteins are known to homo- and heterodimerize selectively 
4.  It is this selective dimerization that helps impart DNA binding specificity to these 
transcription factors.  In many cases, bZIP proteins have been shown to be 
unstructured in the absence of DNA but adopt structure in the DNA-bound form 4a, 4g, 
17, 20. While ATF5 appears to lack higher order structure in solution, because ATF5 
can bind specifically to the CRE DNA motif in the absence of another protein, DNA 
binding may induce formation of a coiled-coil homodimer. ATF4, the closest 
homolog of ATF5 at 74% sequence homology, has been shown to homo- and 
heterodimerize 21. Currently, a high-resolution structure of a homodimer of ATF4 or 
ATF5 is not available, but a crystal structure of a heterodimer involving ATF4 has 
been reported [40]. Based on strong sequence identity, this structure can be used to 
inform our understanding until a structure of ATF5 is completed. In the reported 
structure ATF4 forms a heterodimeric coiled-coil with CCAAT Enhancer-binding 
Protein β (C/EBPβ). The ATF4 helix is unusually straight, and heterodimerization is 
accomplished because C/EBPβ is able to wrap around ATF4. The rod-like 
conformation observed for ATF4 in the heterodimeric complex seems incompatible 
with homodimer formation, suggesting an alternative structure must be employed by 
the homodimer to accomplish DNA binding.  
 Disulfide bond formation commonly is considered to be an artifact of in vitro 
experiments, and this may be the case in our studies. However, in recent years data 
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has been accumulating to support that oxidation and reduction of many proteins 
regulates their activity in vivo 22.  Furthermore, it has been previously reported that 
DNA binding of the Fos/Jun bZIP heterodimer is modulated by redox redulation of a 
conserved cysteine residue 23.  Examination of the ATF4 structure reveals the Cys 
involved in homodimeric cross-linking is positioned at the interface of the coiled-coil 
structure. A cysteine is present in the analogous position in the bZIP domain of 
ATF5, and this is the only Cys present in either protein as expressed. In the ATF4-
C/EBPβ structure paper the authors noted the need to use a mutant of the ATF4 
protein in which the cysteine residue in the center of the bZIP domain was mutated to 
alanine in order to prevent precipitation and obtain the crystal structure of the 
heterodimer. Likewise, inclusion of reducing agent during refolding helped minimize 
precipitation of ATF5. This difference in solubility indicates that cross-linking alters 
the structure of these transcription factors. Our solution studies show that the physical 
association of ATF5 monomers is weak, with little coiled-coil structure observed 
even at high protein concentration. If the homodimer has a function in vivo, then 
obviously cross-linking would greatly stabilize the interaction. In ATF5 the 
intermolecular disulfide bond forms readily in the absence of reducing agents and is 
slowly reversible with the addition of 1000-fold excess of the thiol-modulating 
compound DTT. Because ATF5 is upregulated in response to oxidative stress 24, it is 
tempting to speculate that this intermolecular disulfide bond may influence DNA 
binding and/or have functional significance in transcriptional regulation. The research 
presented here provides a basis for conducting a more extensive investigation into 
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how this disulfide linkage affects the structure of the ATF5 dimer and may influence 
its interaction with DNA. 
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CHAPTER 3 
EFFECTS OF DISULFIDE BOND FORMATION AND PROTEIN HELICITY 
ON THE AGGREGATION OF ATF5 
 
3.1 INTRODUCTION 
 Amorphous aggregation is a common phenomenon and a major obstacle to 
handling proteins in vitro.  The aggregation of proteins isolated for use as 
pharmaceutical products poses a serious concern, as aggregates can stimulate the 
immune system, which may have devastating affects on the patient.1 Although the 
study of protein aggregation has wide-reaching implications, the process by which 
aggregation occurs is still difficult to predict.  The study of amyloids has provided 
understanding about the structure and formation of fibrillar aggregates, but a lack of 
data regarding amorphous structure has prevented verifiable application to amorphous 
aggregation. In particular, the role that disulfide bonds play in this process is poorly 
understood, because it varies among different systems.  Reports indicate in some 
instances that disulfide bond formation promotes protein aggregation, yet in others it 
dampens this process.2 These effects appear to be largely protein specific and 
dependent on features of tertiary structure.  Alpha-helices can also play an important 
role in aggregation.  In most instances, retention of α-helical structure has been linked 
to improved protein stability; 3 however, several recent reports indicate that α-helical 
structure can facilitate aggregate formation.4 
Reproduced in part with permission from Ciaccio, N. A.; Laurence, J. S., Effects 
of disulfide bond formation and protein helicity on the aggregation of activating 
transcription factor 5. Mol Pharm 2009, 6 (4), 1205-15. Copywrite 2009 
American Chemical Society. 
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 The lack of understanding surrounding non-fibrillar aggregation is largely due 
to the fact that the assembled species lacks a regular repeating pattern, making it is 
difficult to study.  Well-structured and natively disordered proteins do not readily 
aggregate in solution, whereas partially unfolded proteins tend to aggregate rapidly, 
suggesting structured features facilitate aggregation.  Here we present a unique and 
simple system, which is amenable to investigating the mechanism of protein 
aggregation involving a helix to coil transition.  We have previously reported the 
isolation of the bZIP domain of activating transcription factor 5 (ATF5), a protein 
notable for its potential as a pharmaceutical target for treatment of glioblastoma 
multiforme.5 This domain consists of a single α-helix and possesses a single cysteine 
residue.  It is only partially structured (~25% helix) and displays marginal stability in 
solution under physiological conditions.  We have tested solution conditions that 
modulate helical propensity and the oxidation state of the thiol, to successfully 
investigate the role that α-helical structure and disulfide bond formation play in 
protein stability.  These studies have led to the identification of stabilizing conditions 
for ATF5, which will enable further study of the protein as a pharmaceutical target 
and provided a model system for further examination of residue-specific contributions 
to the formation of amorphous aggregates. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Protein Expression and Purification 
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 The cDNA of ATF5 was obtained through ATCC (MGC-842) and the bZIP 
domain was PCR amplified and inserted into a Novagen (San Diego, CA) pET-42b 
vector as described previously.5 Site-directed mutagenesis was performed to create 
the C240A point mutation in the bZIP region using the following primers: 
5’GAGGCCCTGGAGGGCGAGGCCCAGGGGCTGGAGGCACGG (forward 
primer), 5’-CCGTGCCTCCAGCCCCTGGGCCTCGCCCTCCAGGGCCTC (reverse 
primer).  Plasmids were transformed into Novagen BL21(DE3) E. Coli for 
expression.  Purification was done using a refolding procedure described previously.5 
Protein concentrations were determined using a standard Bradford assay.  ATF5 
purification and isolation was confirmed using SDS-PAGE and LC/MS.5 These 
methods were also used to confirm intermolecular disulfide bond formation for wild-
type ATF5.5 Isotopic labeling for two-dimensional NMR was accomplished with the 
substitution of 15N-ammonium chloride. The 15N-ammonium chloride (>99% N-15) 
was obtained from Spectra Stable Isotopes (Columbia, MD). 
3.2.2 Circular Dichroism 
 Circular dichroism (CD) spectra were acquired with a Jasco-810 polarimeter 
(Tokyo, Japan) equipped with a Peltier-type temperature controller and a six-position 
sample holder.  Samples were prepared at a final protein concentration of 100 µM in 
20 mM MES buffer at pH 6.0 in the absence or presence of dithiothreitol (DTT) or 
trifluoroethanol (TFE).  Scans were performed at 4°C from 260 to 190 nm in a 0.1-cm 
path length cell.  A scanning speed of 50 nm/min and a response time of 8 sec were 
used.  The selected bandwidth was 5 nm and the data pitch was 1 nm.  Scans were run 
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in duplicate for each sample and two samples were prepared and analyzed for each set 
of solution conditions.  Using the Jasco Spectra Manager v1.18.00 software the 
measured values were converted to molar ellipticity.  The resulting average and 
standard deviations were plotted for each condition using Plot. Percent helicity was 
calculated using the mean residue ellipticity observed at 222 nm as previously 
described.5-6 
 To evaluate protein stability the absorbance at 222 nm was monitored at a 
function of temperature.  The temperature was adjusted from 4 to 85°C at a ramping 
rate of 15°C/hour and the absorbance was monitored every 0.5°C.  The results were 
converted to molar ellipticity using the instrument software.  Two samples were 
prepared and analyzed for each set of solution conditions.  The resulting average and 
standard deviations were plotted using Plot.  Midpoints of thermal transition were 
calculated using Microcal Origin sigmoidal fit graphing tools. None of the solution 
conditions used produced signals above background at any temperature and therefore, 
no buffer subtraction manipulations were performed. 
 A single sample t-test was performed to determine the statistical significance 
in mean CD signal between two populations.  In all cases the theoretical mean 
comprising the null hypothesis consisted of the CD signal observed for the ATF5 
protein in the absence of DTT and/or TFE.  A two-tail p-value is reported.  
3.2.3 Static Light Scattering 
 
 Static light scattering (SLS) data were acquired with a Photon Technology 
International (PTI) spectrafluorometer (Lawrenceville, NJ) equipped with a Peltier-
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type temperature controller and a four-position sample holder. Samples were prepared 
at a final protein concentration of 100 µM in 20 mM MES buffer at pH 6.0 in the 
absence or presence of dithiothreitol (DTT) or trifluoroethanol (TFE).  The intensity 
of scattered light was measured as a function of temperature and detected at an angle 
of 90° to the light source by a photomultiplier tube.  An arc lamp white light source 
was used in all cases.  The excitation wavelength was set at 275 nm.  The emission 
wavelength range was set from 250 nm to 350 nm.  Spectra were obtained following a 
5 min equilibration period at each temperature.  Data were collected every 2.5°C 
between the temperature range of 4 to 81.5°C.  The background was subtracted from 
each data point based on a blank containing the corresponding buffer solution.  Two 
samples were prepared and analyzed for each set of solution conditions.  The 
resulting average and standard deviations were plotted using Plot. 
3.2.4 Dynamic light scattering  
  
 The average hydrodynamic diameter was monitored as a function of 
temperature using a Brookhaven (Holtsville, NY) BLS-9000 DLS instrument 
equipped with a 50 mW HeNe diode laser operating at 532 nm and a Brookhaven BI-
200SM goniometer.  Samples were prepared in 20 mM MES buffer pH 6.0 at a final 
concentration of 100 µM.  Five consecutive 30 sec data collection intervals were 
taken every 2.5°C over the range of 10 to 90 °C.  Light scattering was monitored 90° 
to the incident light and autocorrelation functions were generated using a Brookhaven 
BI-9000AT digital autocorrelator.  Analysis was performed using the method of 
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cumulants.  The hydrodynamic diameter was calculated from the translational 
diffusion coefficient using the Stokes-Einstein equation.7 
3.2.5 Nuclear Magnetic Resonance 
 Two-dimensional 1H-15N heteronuclear single quantum coherence (HSQC) 
spectra were recorded at 25°C using a Bruker AVANCE 800 MHz spectrometer 
equipped with a triple-resonance CRYO-probe with pulse field gradients. Samples 
were prepared at a concentration of 0.2 mM in 50 mM sodium phosphate, 100mM 
NaCl pH 6.5, containing 5% D2O.  Water suppression was accomplished using flip-
back pulses. Data were acquired in 128 scans with 2048 points in 1H and 128* 
increments in 15N. 1H chemical shifts were referenced with respect to an external DSS 
standard in D2O.8 Indirect referencing relative to 1H was determined for 15N, 
assuming a ratio of 15N/1H = 0.101329118.  Data were processed using NMRPipe and 
Sparky software.9 
 
3.3 RESULTS  
3.3.1 Effects of Disulfide Bond Formation on ATF5 Structure and Stability 
 CD spectroscopy was used to investigate the influence of a single 
intermolecular disulfide bond (C240-C240) on the structure of the bZIP domain of 
ATF5.  The spectra reveal absorption characteristics consistent with the presence of 
α-helical structure for both the disulfide-bound dimer and the C240A monomer 
(Figure 3.1A).  This is depicted by the double absorption minima pattern detected at 
222 nm and 208 nm.10 The ratio of 222 to 208 nm is 0.84 for wild type and 0.85 for 
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C240A, which is consistent with a-helical but not coiled-coil structure.11 An increase 
in helical content is observed for the dimer in comparison to the monomer.  This 
difference can be quantified for each species using the mean residue ellipticy at 222 
nm.5-6 The percent helicity calculated for the dimer under these conditions is 23.4% ± 
0.3%, whereas the percent helicity of the C240A monomer is 19.0% ± 1.0% (p-value 
< 0.02).  
 Upon the addition of reducing agent to wild-type (WT) ATF5 (10 mM DTT), 
a decrease in the CD signal that corresponds to α-helix is observed (Figure 3.1B).  
The absorption intensity for the reduced WT more closely resembles that of the 
C240A monomer under reducing conditions with a calculated percent helicity of 
17.9% (± 0.2%) and 16.7% (± 0.1%), respectively (p-value > 0.2).  This suggests the 
intermolecular disulfide bond is responsible for the increased helicity originally 
observed for the dimeric species.  It is important to note that the decrease in 
absorption intensity observed at 208 nm relative to 222 nm in the presence of DTT is 
due to substantially increased interference caused by DTT on the detection at shorter 
wavelengths.  For this reason, absorption measurements taken at wavelengths below 
210 nm in the presence of DTT should be considered less accurate. As such, the ratio 
of 222 nm to 208 nm was not assessed because the interpretation of this value is also 
unreliable for determining a-helical vs coiled-coil content.  
 The impact of the intermolecular disulfide bond on thermal stability was 
evaluated by monitoring the α-helix CD absorption signal at 222 nm as a function of 
temperature. A decrease in absorption signal at 222 nm indicates a loss of secondary 
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structure, which reflects protein unfolding. The disulfide-bound dimer is more stable 
than the C240A monomer.  The calculated melting temperature (Tm) of the dimer is 
55.5°C, whereas it is 15.9°C for the monomer (Figure 3.2A).  In the presence of 
reducing agent (10 mM DTT) the Tm for the C240A mutant remains relatively 
unchanged (15.1°C), whereas the melting curve for the dimer shifts dramatically to 
more closely resemble that of the monomer (Figure 3.2B).  The calculated transition 
temperature for the dimer under these conditions is 19.9°C.  Notably, unfolding of all 
forms of ATF5 was found to be largely irreversible due to precipitation of aggregated 
species (data not shown).  
 The effect this intermolecular disulfide bond has on protein aggregation was 
then evaluated using a static light scattering assay.  The intensity of scattered light 
was measured as a function of temperature for the two forms of ATF5. In this assay, 
an increase in the intensity of scattered light indicates increased aggregate formation. 
The data show that the onset of aggregation is more rapid, and the extent of 
aggregation is greater for the C240A mutant compared to the WT under non-reducing 
conditions (Figure 3.3A).  The onset of aggregation is more gradual and the extent 
lessened for the disulfide-bound dimer (Figure 3.3A).  Upon reduction of the disulfide 
bond via the addition of reducing agent (10 mM DTT), the scattering profile of the 
dimer more closely parallels that of the C240A monomer (Figure 3.3B).  The 
decrease in signal seen at higher temperatures in Figure 3B indicates the formation of 
very large aggregates that have settled out of solution, resulting in diminished 
absorbance intensity. This was verified using dynamic light scattering analysis, which 
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indicated that the average hydrodynamic diameter of protein in solution was much 
greater in the presence of DTT (data not shown). Clearly, reduction of the disulfide 
bond decreases thermal stability, as the two proteins now behave similarly. 
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Figure 3.1 (A) CD absorption spectra of the disulfide-linked ATF5 dimer (red 
upright triangles) and the C240A monomer (blue downturned triangles) in the 
absence of 10 mM DTT.  (B) CD absorption spectra of the CD absorption spectra of 
the ATF5 dimer (red upright triangles) and the C240A monomer (blue downturned 
triangles) in the presence of 10 mM DTT. 
 
 
 
 
Figure 3.2 (A) CD absorption at 222 nm of the disulfide-bound ATF5 dimer (red 
upright triangles) and C240A monomer (blue downturned triangles) in the absence of 
10 mM DTT as a function of temperature.  (B) CD absorption at 222 nm of the 
disulfide-bound ATF5 dimer (red upright triangles) and C240A monomer (blue 
downturned triangles) in the prescence of 10 mM DTT as a function of temperature. 
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Figure 3.3 (A) SLS analysis of the disulfide bound ATF5 dimer (red upright 
triangles) and C240A monomer (blue downturned triangles) in the absence of 10 mM 
DTT as a function of temperature.  (B) SLS analysis of the ATF5 dimer (red upright 
triangles) and C240A monomer (blue downturned triangles) in the presence of 10 
mM DTT as a function of temperature. 
 
 
 Percent Helicity 
(%) 
Melting 
Temperature 
(°C) 
Maximum 
Intensity of 
Scattered 
Light (CPS) 
WT, no 
DTT 
23.4 ± 0.3 55.5 35,815 ± 2,658 
WT + DTT 17.9  ± 0.2 19.9 173,132 ± 
4,151 
C240A, no 
DTT 
19.0 ± 1.0 15.9 143,560 ± 
13,475 
C240A + 
DTT 
16.7 ± 0.1 15.1 175,415 ± 
1,149 
 
Table 3.1 Summary of the results from the CD and SLS experiments for the WT and 
C240A forms of ATF5 in the absence and presence of the 10 mM DTT.     
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3.3.2 Effects of TFE-induced Helicity on ATF5 Structure and Stability 
 The effect that α-helical structure has on protein stability was evaluated using 
the addition of the co-solvent trifluoroethanol (TFE) to induce helical structure.  The 
use of TFE for the purpose of inducing protein structure is common and well cited.12 
TFE is added to peptides to enhance α-helicity, because the solubility of the 
backbone changes.  Low percentages of TFE typically increase helicity, but at high 
concentrations (often >40%) β-sheets may form in some peptides.12a The impact of 
TFE on the structure of ATF5 was assessed using CD spectroscopy.  The helical 
content of both the disulfide-bound dimer and the C240A monomer increased in a 
dose-dependent fashion upon the addition of TFE within the experimental range used 
(Figure 3.4).  The increase in helicity observed for a given amount of TFE added was 
greater for the C240A mutant than for the dimer, but at 10% TFE and above both 
forms displayed equivalent amounts of helical structure.  The percent helicity was 
quantified as described above for both forms of ATF5.  The dimer displayed a percent 
helicity of 25.5% (± 0.6%), 30.8% (± 0.6%), and 39.3% (± 1.0%) in the presence of 
no TFE, 10% TFE (p-value < 0.1) and 20% TFE (p-value < 0.05), respectively.  The 
comparative values for the C240A monomer are 19.5% (± 0.3%), 30.5% (± 0.3%), 
and 42.0% (± 2.2%) in the presence of no TFE, 10% TFE (p-value < 0.02) and 20% 
TFE (p-value < 0.1), respectively.    
 The thermal stability of both forms of ATF5 in the presence of increasing 
concentration of TFE was investigated by monitoring the α-helical CD absorption 
signal at 222 nm as a function of temperature.  The melting profiles of both forms 
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changed in the presence of TFE (Figure 3.5).   The data show that increasing the 
helicity of either form of ATF5 improves thermal stability, because greater α-helical 
structure is retained at all temperatures in the presence of TFE.  A standard 
quantitative analysis comparing Tm values is not possible for these data, because the 
melting profiles in the presence of 10% and 20% TFE could not be fit to a sigmoidal 
curve.  The melting temperature calculated for the WT form of ATF5 in the absence 
of TFE is 56.0°C.  At that same temperature in the presence of 10% and 20% TFE, 
there is greater helical structure present.  The molar ellipticity values for the WT 
dimer at 56°C in the presence of 0%, 10% and 20% TFE are -426,189, -581,870, and 
-630946, respectively.  This equates to approximately 9% more α-helix at 10% TFE 
than at 0% TFE, and 3% more helix at 20% TFE than at 10%.  The melting 
temperature calculated for the C240A monomer in the absence of TFE is 17.2°C.  
The molar ellipticity values for the C240A mutant at 17°C in the presence of 0%, 
10% and 20% TFE are -428,822, -653,246 and -846,000, respectively, equating to 
12% more helix at 10% TFE than 0% TFE, and 11% more helix at 20% TFE than 
10% TFE. 
 Analysis of static light scattering data was used to evaluate the effect of TFE 
concentration on protein aggregation.  Increasing concentrations of TFE diminished 
aggregation for both the cross-linked WT dimer and the C240A monomer (Figure 
3.6).  The maximum intensity of scattered light in counts per second detected for the 
WT form is 259,404, 150,731 and 139,743 in the presence of 0%, 10% and 20% TFE, 
respectively.  Notably, a greater difference in the extent of aggregation is observed 
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between 0% and 10% TFE than between 10% and 20% TFE.  This same trend is 
observed for the C240A monomer, where the maximum intensity of scattered light in 
counts per second detected in the presence of 0%, 10% and 20% is 779,386, 277,567, 
and 248,188, respectively.  The greatest impact on aggregation in all cases is 
observed for the C240A mutant in the presence of 10% TFE, where the inclusion of 
the co-solvent dramatically reduces the onset and extent of aggregation.  The impact 
on aggregation for the WT form at the same concentration of 10% TFE is much less 
dramatic, even though the percent helicity induced is roughly the same as that of the 
C240A monomer (approximately 30%).  At low temperatures, the addition of TFE 
leads to a small amount of increased light scattering for both the WT and C240A.  
There is more scattering at 20% TFE compared to 10% TFE, suggesting that an 
alternative mode of association may be responsible for aggregation in the TFE-
containing samples. 
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Figure 3.4 (A) CD absorption spectra of the disulfide-linked ATF5 dimer in the 
presence of increasing amounts of TFE: purple squares (no TFE), green circles (10% 
[v/v] TFE) and blue diamonds (20%[v/v] TFE).  (B) CD absorption spectra of the 
ATF5 C240A monomer in the presence of increasing amounts of TFE: purple squares 
(no TFE), green circles (10% [v/v] TFE) and blue diamonds (20%[v/v] TFE). 
 
 
 
Figure 3.5 (A) CD absorption at 222 nm of the disulfide-linked ATF5 dimer as a 
function of temperature in the presence of increasing amounts of TFE: purple squares 
(no TFE), green circles (10%[v/v] TFE) and blue diamonds (20%[v/v] TFE).  (B) CD 
absorption at 222 nm of the ATF5 C240A monomer as a function of temperature in 
the presence of increasing amounts of TFE: purple squares (no TFE), green circles 
(10%[v/v] TFE) and blue diamonds (20%[v/v] TFE). 
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Figure 3.6 (A) SLS analysis of the disulfide-linked ATF5 dimer in the presence of 
increasing amounts of TFE: (purple squares) no TFE, (green circles) 10% TFE and 
(blue diamonds) 20% TFE.  (B) SLS analysis of the ATF5 C240A monomer in the 
presence of increasing amounts of TFE: (purple squares) no TFE, (green circles) 10% 
TFE and (blue diamonds) 20% TFE. 
 
 
 Percent Helicity 
(%) 
Melting 
Temperature 
(°C) 
Maximum 
Intensity of 
Scattered 
Light (CPS) 
WT, no TFE 25.5  ± 0.6 56.0 259,404 ± 
15,061 
WT, 10% 
TFE 
30.8 ± 0.6 NA 150,731 ± 
6,096 
WT, 20% 
TFE 
39.3 ± 1.0 NA 139,743 ± 
6,404 
C240A, no 
TFE 
19.5 ± 0.3 17.2 779,386 ± 
87,881 
C240A, 10% 
TFE 
30.5 ± 0.3 NA 277,567 ± 
13,598 
C240A, 20% 
TFE 
42.0 ± 2.2 NA 248,188 ± 
9,972 
 
Table 3.2 Summary of the results from the CD and SLS experiments for the WT and 
C240A forms of ATF5 in the presence of increasing amounts of the co-solvent TFE. 
A melting temperature could not be calculated for the protein in the presence of 10% 
and 20% TFE, because the data could not be fit to a sigmoidal curve.  NA= not 
applicable. 
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3.3.3 NMR Analysis of the Effects of Disulfide Bond Formation on ATF5 
Structure 
 
 NMR experiments were performed to evaluate general differences in structure 
between the WT and C240A forms of ATF5 at higher resolution.  The 2D 1H-15N 
HSQC experiment used here selectively detects all NH pairs in the protein and 
correlates each 1H to the directly attached 15N atom.  The resultant spectrum is 
considered a “fingerprint” of the protein, because the chemical shifts depicted reflect 
the conformationally-weighted average of the environment experienced by the nuclei, 
which is defined by the overall protein fold.  Consequently, the 1H-15N HSQC 
experiment can provide a quick indication of protein structure. A well-behaved 
globular protein will display good signal dispersion, typically ranging from 6 to 12 
ppm on the 1H-axis and 100-140 ppm on the 15N-axis.  This dispersion results from 
the presence of stable, structural features that confine the individual nuclei to unique 
chemical environments.  More disordered proteins typically have peaks clustered 
more closely around random coil values (~8.3 ppm in 1H).  This is because, on 
average, the nuclei experience more similar chemical environments in solution than in 
the structured protein. The HSQC spectra of proteins composed of only a single helix, 
like the bZIP of ATF5, are difficult to interpret without full assignments and 
additional data, because in a standard alpha helix, all the amides are in similar 
environments, which can result in overlapping NMR signals.  Typically, when bZIP 
proteins functionally dimerize they interact to form a two-stranded coiled-coil.  
Higher-order protein structure, such as coiled-coil, would place the NH nuclei in 
more distinct chemical environments, resulting in greater dispersion of the NMR 
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signal, as has been demonstrated experimentally for a number of bZIP proteins 
examined structurally using solution NMR.13  
 An overlay of the 2D HSQC spectrum of the C240A mutant onto the WT 
spectrum shows that the chemical shifts for both forms are largely clustered around 
8.3 ppm in 1H and only a few differences in resonance positions between the spectra 
are apparent (Figure3.7). This indicates the average structure of the two forms is quite 
similar and both proteins are conformationally labile. The limited chemical shift 
dispersion observed for both forms of ATF5 represents α-helix and/or random coil 
structure. The lack of dispersion in the NMR spectra further indicates coiled-coil 
structure is not developed, even in the obligate wild-type dimer. This is consistent 
with the CD spectra in which the ratio of 222 to 208 nm indicate a-helix is present but 
coiled-coil structure is not. The unique red peaks in the WT dimer likely correspond 
to residues adjacent to C240 involved in the helical region that are stabilized by 
disulfide bond formation.  The NH signal generated by the side chains of Asn and Gln 
residues cluster in a different chemical shift range and account for the signal observed 
between 6.8 and 7.6 ppm on the 1H -axis.  There is little evidence for the existence of 
a coiled-coil structure for either form of ATF5, even at the high concentrations 
required for these studies. These data suggest that despite the presence of 23% helical 
content in the covalent dimer and its resistance to aggregation when the helix is 
maintained, ATF5 does not develop well-defined tertiary structure.  Interestingly, the 
addition of 20% TFE alters the spectrum to only a small extent (data not shown), 
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suggesting TFE may temporarily stabilize residues already prone to helix formation 
rather than propagating helicity to other portions of the sequence. 
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Figure 3.7 2D 1H-15N HSQC spectrum of 0.2 mM 15N-labeled ATF5 WT dimer (red 
peaks) and C240A monomer (blue peaks) in 20 mM MES, pH 6.5. 
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Figure 3.8 Helical wheel diagram of an ATF5 homodimer depicting standard coiled-
coil interactions. Favorable interactions that would stabilize formation of a coiled-coil 
are delineated in black.  Repulsive interactions that would be destabilizing are shown 
in red. The diagram reveals the lack of consensus among homotypic interactions to 
support coiled-coil stabilization. 
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Figure 3.9 Sequence alignment of the bZIP domain of ATF4 and ATF5.  The basic 
residues comprising the basic DNA binding domain are highlighted in blue.  The 
leucine and valine residue located in the d-position of the leucine zipper heptad are 
highlighted in red.  The unusual cysteine residue poised to form an intermolecular 
disulfide bond is underlined.  The region of ATF5 most likely to form α-helical 
structure is boxed. 
 
 
 
 
 
Figure 3.10 Aggregation model of ATF5.  Slow aggregation of the cross-linked 
ATF5 dimer is facilitated by antiparallel association of the disordered valine-
containing region (φ).  Reduction of the disulfide bond creates the monomeric 
species, which displays decreased helicity and participates in fast aggregation through 
antiparallel alignment of the same valine-containing region. The N-terminal basic 
domain is illustrated by the addition of symbols indicating positive charge (+).  The 
helical portion of the leucine zipper is depicted in blue.  Note: A limited set of 
arrangements is shown here, but others are equally possible. 
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3.4 DISCUSSION 
 
 ATF5 belongs to the basic leucine zipper (bZIP) family of transcription 
factors.  These proteins function as dimers that bind DNA and regulate transcription.  
The bZIP domain, present in all family members, contains a repeating pattern of 
leucine in every seventh position, which facilitates dimerization through formation of 
a parallel two-stranded coiled-coil.14 Favorable hydrophobic interactions between 
residues in the a and d positions of the leucine zipper heptad in conjunction with 
attractive electrostatic interactions between residues in the e and g positions typically 
drive coiled-coil formation in bZIP proteins.14 The basic regions of each monomer 
then bind DNA in what has been described as a  “scissors-grip” model of binding.15 
bZIP proteins can either homodimerize or heterodimerize with other bZIP family 
members.  Previous findings suggest that ATF5 forms a bZIP homodimer (Figure 
3.8).16 We have identified some favorable interactions that exist in our helical wheel 
diagram of the ATF5 homodimer that could assist in formation of a coiled-coil. For 
instance, the leucine residues in the d position (boxed in black) have a high 
propensity to adopt a helical conformation and are known to pack favorably in two-
stranded coiled-coils.17 We have shown that disulfide bond formation at the cysteine 
residue in the a position (boxed in black) retains helical structure, which could be a 
stabilizing force for a coiled-coil.  Additionally, there are a few favorable electrostatic 
interactions that exist between residues in the e and g positions (depicted by black 
double-headed arrows and boxed) that could help stabilize a coiled-coil homodimer. 
However, there are also several unfavorable interactions present here that are not 
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found in other bZIP coiled-coils.  The valine residues in the d position (outlined in 
red) have a much lower propensity to adopt helical structure.17a  β-branched amino 
acids, like valine, are also not favored in the packing arrangement of two-stranded 
coiled-coils.17b, c A series of unfavorable electrostatic interactions exist between 
residues in the e and g positions (delineated by red double-headed arrows and boxed) 
that would further prevent formation of a stable coiled-coil.  We have collected 
structural data on the bZIP domain of ATF5 at high concentrations using CD and 
solution NMR,5 and our data indicate that the ATF5 protein does not form a stable 
coiled-coil in solution under physiological pH, ionic strength and reducing 
conditions.5 The absence of valine residues and repulsive electrostatic interactions in 
the ATF4 and other bZIP coiled-coil structures implies that these features are 
responsible for the prevention of a stable coiled-coil for the ATF5 homodimer.  
 ATF5 shares 74% sequence homology with another bZIP protein family 
member, ATF4 (Figure 3.9).  A crystal structure has been solved for ATF4, in which 
the protein participates in formation of a bZIP heterodimer with CCAAT enhancer 
binding protein β (C/EBPβ).18 In this structure, ATF4 is shown to exist as a very 
straight α-helix, while C/EBPβ curves to wrap around ATF4 and create the coiled-
coil.  This is a unique feature of ATF4, as most bZIP proteins display more flexibility, 
with two bZIP monomers curving equally to wrap around each other.19 The structure 
suggests that the rigidity of the ATF4 α-helix disfavors homodimerization, i.e. coiled-
coil formation, and therefore must dimerize with a more flexible partner.  The lack of 
stable homodimer formation under reducing conditions suggests ATF5 may 
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heterodimerize in vivo and that it is prone to aggregation in vitro because its 
hydrophobic side chains are exposed and unable to form native interactions without 
the alignment imposed by covalent attachment. 
 Alternatively, it has been suggested that intermolecular disulfide bond 
formation might facilitate formation of an ATF4 or ATF5 homodimer.18 A unique 
cysteine residue is located at the center of the bZIP region of ATF4.18 This analogous 
cysteine is positioned such that it would be at the interface of a coiled-coil dimer.  
ATF4 and ATF5 are the only bZIP proteins that contain a cysteine residue in this 
position, suggesting a functional role for this residue in vivo.  We have collected 
NMR data in the presence and absence of this intermolecular disulfide bond for 
ATF5. The notable lack of dispersion in 1H signal in the spectra of both the reduced 
monomer and oxidized dimer compared to spectra of other coiled-coil proteins 
indicates disulfide bond formation at this position does not confer formation of a 
stable coiled-coil (Figures 3.7 and 3.8). This disulfide bond does, however, play a role 
in retention of α-helical structure and physical stability of the protein to resist 
aggregation.  If homodimerization has a biological function, the protein is likely to be 
redox regulated, as has been reported for other transcription factors.20 
 A naturally occurring mutant of apolipoprotein A-I (ApoA-I) known as the 
Milano variant (ApoA-IM) was found to affect the stability of this protein in a parallel 
manner to that observed for ATF5. The Milano mutation introduces a non-native Cys 
residue that results in the formation of a disulfide-bonded homodimer. Cys 
substitution significantly increases both the percent helical content and the stability of 
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this protein at high concentration.21 Cross-linking stabilizes a conformational change 
in ApoA-IM that increases the helical content to match that of the native dimerized 
form, which is present at higher concentrations of protein.  At lower protein 
concentration this mutation and other substitutions at the same site leads to 
diminished helicity and stability due to disruption of a salt bridge.22 Addition of TFE 
to monomeric ApoA-I also increases its helical content to match that of the Milano 
form and concomitantly improves stability of the native protein against aggregation. 
ApoA-I is prone to form amyloid aggregates in vivo, whereas the disulfide-bound 
Milano form resists aggregation.23 Interestingly, mutation at the same or adjacent 
positions in the protein that do not confer covalent attachment render ApoA-I more 
susceptible to aggregation.23 Despite that ApoA-I and ATF5 are unrelated in sequence 
or function, these two systems display parallel behaviors with respect to the influence 
of helicity and disulfide cross-linked dimerization on stability and aggregation. 
Further investigation of ATF5 and comparison to ApoA-I may provide insights to 
better understand the basis of how helical structure and dynamics influence stability 
and aggregate formation. 
 The bZIP domain of ATF5 contains several valine residues instead of leucine 
residues at the C-terminal end of this region.  While valine residues are commonly 
located in the a-position of the leucine zipper heptad, they rarely occupy the d-
position.  ATF5 is the only bZIP protein to possess three consecutive valines in this 
domain.  ATF4 encodes only a single valine residue in the last d-position of its bZIP 
domain.  It is not known what affect these β-branched amino acids would have on the 
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binding partner selectively of ATF5 in vivo, but they seem to prevent coiled-coil 
formation and are likely to be a key component of the protein’s instability in vitro. 
 Our data show that the bZIP domain of ATF5 is only partially structured in 
solution, with its percent helicity increasing from 19.0% to 23.4% in the presence of 
the intermolecular disulfide bond.  Using the DISEMBLTM server we predicted the 
intrinsic disorder of this domain (data not shown).24 The N-terminal basic domain 
(residues 203-238) and the end of the C-terminal leucine zipper domain (residues 
275-282) are the most likely regions to be disordered.  Additionally, a number of 
studies have shown that the helical propensity of leucine is much greater than 
valine.17a This suggests that the central portion of the leucine zipper of ATF5 is most 
likely to be helical.  There are seventeen residues between the cysteine at position 240 
and the valine at position 257, which make up the first half of the leucine zipper 
domain.  If this region displayed 100% helicity and the rest of the protein was 
disordered, the predicted percent helicity would be 22.8%.  This matches closely with 
the experimental values obtained for ATF5.  An intermolecular disulfide bond 
positioned at cysteine 240 would likely help to stabilize the helical structure in this 
region by constraining the two chains and increasing intermolecular contact between 
them.   
 Computational methods for predicting protein aggregation have been 
developed, and we used several to examine ATF5. TANGO is a statistical mechanical 
model used to identify nucleation sites for aggregation based on the observations that 
aggregates often contain increased β-structure and the core regions of an aggregate 
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are completely buried, such that nucleating sequences will have their hydrogen 
bonding potential largely satisfied.25 This program predicts that the region most likely 
to initiate aggregation in ATF5 lies between residues 260 and 276.  This corresponds 
to the valine-containing portion of the leucine zipper, which is largely hydrophobic 
(Figure 3.9).  AGGRESCAN is another sequence-based tool, which relies upon the 
aggregation-propensity for each of the individual amino acids to identify sequences 
likely to aggregate.26An evaluation of the bZIP domain of ATF5 identified the region 
contained between residues 265 and 273 as most likely to aggregate, which again, 
falls within the valine-containing portion of the leucine zipper.  Based upon this 
information, it is likely that the structural features demonstrated to impart improved 
stability to ATF5 function protect the less-structured and aggregation-prone valine-
containing portion of the protein from intermolecular association. A third program 
was used to evaluate the propensity of protein molecules to self-associate.  Prediction 
of amyloid structure aggregation (PASTA) is based on the alignment observed in 
most cross-β structures.27 PASTA predicted that it is unlikely for ATF5 to form cross-
β fibrillar aggregates, which is consistent with our experimental observations of 
amorphous aggregates.  The PASTA results, however, indicated that the antiparallel 
alignment of ATF5 in solution is energetically preferred over parallel alignment.  
This small preference could explain why aggregates form more rapidly between 
monomers. Covalent dimerization may not so much alter the structure of the 
monomer as constrain the Val-containing sequences in close proximity and provide 
an adjacent hydrophobic surface with which to interact.28 
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 We have shown that the retention of α-helical structure through the formation 
of an intermolecular disulfide bond prevents rapid, thermally-induced protein 
aggregation.  The addition of the co-solvent TFE also diminishes protein aggregation 
and induces α-helical structure, although the correlation between these two events is 
less clear since TFE affects multiple solution parameters that could also influence 
aggregation (i.e. dielectric constant, hydrogen-bonding pattern etc.).  Based on the 
prediction results derived from first principles, it is most likely that the disordered 
regions of ATF5 play a role in initiating the process of aggregation rather than the 
uncoiled helical sequence.  As electrostatic repulsion will dominate and prevent 
association between the basic regions, we propose that the hydrophobic residues 
present in the valine-containing portion of the protein are involved in initiating 
protein aggregation.  Reduction of the disulfide bond at C240 would result in greater 
conformational freedom and exposure of hydrophobic residues in this region, which 
would increase protein aggregation.  This explains why aggregation proceeds so 
much more quickly for the reduced WT and C240A monomer.  The addition of TFE 
could potentially stabilize the helicity of the Leu-containing region, providing 
enhanced rigidity and reduced dynamic motion in the Val-containing region that 
would diminish solvent exposure and prevent self-association.  Based upon our 
experimental evidence along with the results acquired using the computational tools 
identified above, we have proposed a model that depicts the aggregation mechanism 
of ATF5 (Figure 3.10).  In using such a simple system to investigate protein 
aggregation, we have clear evidence to support the notion that increasing the 
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structural integrity of native α-helices improves protein physical stability.  This 
conclusion has implications for handling other helical proteins in vitro and provides a 
basis for further investigating amorphous aggregation at higher resolution. 
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CHAPTER 4. 
EFFECTS OF THE VALINE ZIPPER REGION ON THE AGGREGATION 
OF THE BZIP DOMAIN OF ACTIVATING TRANSCRIPTION FACTOR 5 
 
4.1 INTRODUCTION 
Protein aggregation is a major concern of the biopharmaceutical industry.1 
The aggregation of protein products may not only lead to a decrease in drug potency, 
but aggregated species can also display enhanced immunogenicity.2 Consequently, 
controlling the formation of protein aggregates in a pharmaceutical formulation is of 
great importance.  The difficulty in preventing aggregation partially stems from our 
lack of understanding of the mechanism by which aggregates form.  In particular, we 
do not understand the role that protein structure plays in this process.  Increasing 
evidence suggests that partially folded protein intermediates critically influence the 
aggregation pathway; however, this relationship remains ill-defined.3  
 Two general categories of protein aggregates have been reported in the 
literature: amyloid fibrils and amorphous aggregates.4 Fibrillar aggregates have 
received much attention due to their association with a growing number of serious 
disease states for which limited treatment options exist.4c, 5 They are characterized by 
a cross-beta structure, in which the beta strands align in a highly organized format 
along the long-axis of the fibril.4c, 5a, 6 Amorphous aggregates are often associated 
with recombinant protein production and purification in vitro; however increasing 
evidence indicates that a number of proteins can develop into both fibrillar and 
Reproduced in part with permission from Molecular Pharmaceutics, 
submitted for publication. Unpublished work copywrite 2011 American 
Chemical Society. 
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amorphous aggregates in vitro.7 The nature of the aggregated species is highly 
dependent upon protein sequence and solution conditions that control protein 
conformation.7 Amorphous aggregates are so named because unlike fibrillar 
aggregates, they do not display long-range order.3h, 4a, 4d However, these aggregates do 
possess structure and, typically, an increase in intermolecular beta-sheet content is 
observed compared to the native state.3h, 4a, 8 This is not true in all cases, and the 
development of alternative structures, including alpha helix, has been reported in 
aggregates.3g, 9 It is currently unclear how the amino acid sequence and higher order 
structure directs aggregate assembly and organization. 
 We have previously reported the production of the basic leucine zipper (bZIP) 
domain of Activating Transcription Factor 5 (ATF5), a notable protein target for 
treatment of glioblastoma.10 Because of its propensity to aggregate in vitro, we have 
used ATF5 as a model system to investigate protein aggregation.11 Our previous data 
indicate that disulfide bond formation prevents the formation of large amorphous 
protein aggregates through improved retention of alpha-helical structure.11 
Computational analysis predicted that the C-terminal region, which contains a series 
of three valine residues (V257, V264 and V271) in lieu of the conserved leucine 
residues typically observed in these positions, most likely facilitates aggregation.11 
We suggested that disulfide bond formation minimized solution exposure of this C-
terminal region through improved structural retention, resulting in diminished protein 
aggregation.11 The work presented here further characterizes the contribution of this 
C-terminal region to the aggregation of ATF5.   
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 A mutant form of the ATF5 protein that lacks the C-terminal region (residues 
257-282) was created using site-directed mutagenesis.  This variant (V257STOP) was 
created via the insertion of a stop codon immediately preceding the first valine 
residue (V257) in this region.  The structure of the purified mutant form of ATF5 was 
evaluated using circular dichroism spectroscopy (CD), Fourier transform infrared 
(FTIR) spectroscopy and two-dimensional nuclear magnetic resonance (NMR) 
spectroscopy.  The results were compared with that of the wild-type (WT) form of 
ATF5 to determine the effect of C-terminal truncation on protein structure.  The 
extent of thermal aggregation of both proteins was monitored using static light 
scattering (SLS) analyses and dynamic light scattering (DLS) analyses.  Structural 
changes that occurred during the aggregation process were evaluated using FTIR 
analysis.  These data were collectively used to compare the formation and growth of 
protein aggregates of both the WT and V257STOP forms of ATF5 and identify 
correlations between protein structure and aggregate development.  Our data indicate 
that removal of the C-terminal region of ATF5 changes the structure of the protein 
and the mechanism of thermally induced protein self-association. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Protein Expression and Purification  
 
 The cDNA of ATF5 was obtained through ATCC (MGC-842), and the bZIP 
domain was PCR amplified and inserted into a Novagen (San Diego, CA) pET-42b 
vector as described previously.10a The V257STOP truncated mutant was generated 
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using site-directed mutagenesis to insert a stop codon at the valine in position 257.  
Mutagenesis was performed by GenScript USA (Piscataway, NJ).  Plasmids were 
transformed into Novagen BL21(DE3) E. Coli for expression.  Cell growth, lysis and 
purification were performed using the procedure described previously with the 
following modification.10a Unlike wild type, the truncated mutant was present largely 
in the soluble fraction following cell lysis and centrifugation.  This fraction was 
heated at 60 °C for 1 hour to precipitate the majority of cellular proteins.  The mutant 
remained soluble under these conditions.  To ensure that any aggregates formed 
during this purification step were eliminated the protein was denatured and 
subsequently subjected to the same refolding procedure as previously described for 
the WT.10a Protein concentrations were determined using a standard Bradford assay.  
The purity of ATF5 was determined using densitometry of Coomassie stained SDS-
PAGE gels.10a This method was also used to confirm intermolecular disulfide bond 
formation using non-reducing conditions.  Isotopic labeling for two-dimensional 
NMR was accomplished during cellular expression with the use of 15N-ammonium 
chloride (>99% N-15; Isotec, St. Louis, MO). 
4.2.2 Circular Dichroism Spectroscopy 
Circular dichroism (CD) spectra were acquired with an Applied Photophysics 
Chirascan (Leatherhead, UK) equipped with a Peltier-type temperature controller and 
a four-position sample holder.  ATF5 WT and V257STOP samples were prepared at a 
final protein concentration of 10 µM in 20 mM MES buffer at pH 6.0.  Scans were 
performed at 10 °C in a 0.1-cm path length cell from 260 to 190 nm.  The selected 
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bandwidth was 4 nm, the data pitch was 1 nm and the sampling time was 0.5 sec.  
Samples were prepared and analyzed in duplicate.  Raw data were converted into 
units of molar ellipticity using the standard formula, [θ] = θ*M*10/C*l, where  [θ] is 
the molar ellipticity, θ is the ellipticy in mdeg, M is the molecular weight in 
mg/mmol, C is the concentration in mg/mL and l is the path length in cm.  
Multiplying by 10 facilitates the conversion from millimoles to decimoles, resulting 
in the final units of deg*cm2*dmol-1.  The resulting average and standard deviations 
were plotted. 
4.2.3 Fourier Transform Infrared Spectroscopy 
Absorption spectra (256 scans) were collected at a 5 mg/mL concentration 
from 900 to 4000 cm-1 at a resolution of 4 cm-1 on a Bruker (Billerica, MA) Tensor 27 
Fourier transform infrared spectrophotometer instrument using a Harrick Scientific 
Products (Pleasentville, NY) BioATR Cell II sample apparatus and a Thermo 
Scientific (Waltham, MA) Haake DC30-K20 refrigerated circulator bath under 
constant nitrogen purge.  The spectrophotometer was equipped with a KBr beam 
splitter and a liquid-nitrogen-cooled mercury cadmium telluride (MCT) detector.  
Reference spectra consisting of 20 mM MES buffer pH 6.0 with or without 10 mM 
dithiothreitol (DTT) were collected prior to each sample solution and subtracted as 
background.  Resultant spectra were first processed using OPUS 6.5 software (Bruker 
Optics).  A correction was performed to minimize absorption interference from 
atmospheric water and carbon dioxide. The minimum and maximum values within 
the amide I region (1600-1700 cm-1) were normalized.  Data were then further 
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processed using GRAMS/AI 8.0 spectroscopy software (Thermo Fisher Scientific).  
A baseline correction was performed, and the data were smoothed using a five-point 
Savitsky-Golay function.  Fourier self-deconvolution was performed and the data 
were fitted by inserting individual Gausssian bands to match the second derivative 
peak position.  Secondary structure assignments were made based upon reference 
spectra reported in the literature.12  
 The temperature was increased from 10 °C to 90 °C to facilitate thermal 
analysis of stability.  Scans (256) were collected every 2.5 °C at a ramping rate of 2.5 
°C per minute.  A reference melt consisting of 20 mM MES buffer pH 6.0 with or 
without 10 mM dithiothreitol (DTT) was collected immediately prior to sample 
analysis and subtracted as background.  The resultant spectra were processed using 
OPUS 6.5 software.  A correction was performed to minimize absorption interference 
from atmospheric water and carbon dioxide.  The minimum and maximum values 
within the amide I region (1600-1700 cm-1) were normalized. The absorbance spectra 
in the Amide I region were plotted as a function of temperature. 
4.2.4 Nuclear Magnetic Resonance Spectroscopy 
Two-dimensional 1H-15N heteronuclear single quantum coherence (HSQC) 
spectra were recorded at 25 °C using a Bruker AVANCE 800 MHz spectrometer 
equipped with a triple-resonance CRYO-probe with pulse field gradients. Samples 
were prepared at a concentration of 1 mM in 20 mM MES buffer pH 6.0, containing 
5% D2O.  Water suppression was accomplished using flip-back pulses.  Data were 
acquired in 8 scans with 1024 points in 1H and 128* increments in 15N.  1H chemical 
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shifts were referenced with respect to an external DSS standard in D2O.13 Indirect 
referencing relative to 1H was determined for 15N, assuming a ratio of 15N/1H = 
0.101329118.  Data were processed using NMRPipe and Sparky software.14  
4.2.5 Static Light Scattering 
 
 Static light scattering (SLS) data were acquired with a Photon Technology 
International (PTI) spectrofluorometer (Lawrenceville, NJ) equipped with a Peltier-
type temperature controller and a four-position sample holder. Samples were prepared 
at a final protein concentration of 100 µM in 20 mM MES buffer at pH 6.0 in the 
presence or absence of 10 mM DTT.  The intensity of scattered light was measured as 
a function of temperature and detected at an angle of 90° to the light source by a 
photomultiplier tube.  An arc lamp white light source was used in all cases.  The 
excitation wavelength was set at 350 nm.  The emission wavelength range was set 
from 300 nm to 400 nm.  Spectra were obtained following a 5-min equilibration 
period at each temperature.  Data were collected every 2.5 °C between the 
temperature range of 4 to 81.5 °C.  The background was subtracted from each data 
point based on a blank containing the corresponding buffer solution.  Two samples 
were prepared and analyzed for each set of solution conditions.  The resulting average 
and standard deviations were plotted. 
4.2.6 Dynamic Light Scattering  
 The average hydrodynamic radius was monitored as a function of temperature 
using a Wyatt Technology Corporation (Santa Barbara, CA) DynaPro Plate Reader 
Plus instrument.  ATF5 WT and V257STOP samples were prepared in 20 mM MES 
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buffer pH 6.0 at a final concentration of 100 µM in the presence or absence of 10 mM 
DTT.  Samples containing the isolated V257STOP aggregate or monomer species 
were prepared at a 40 µM concentration in phosphate buffered saline (PBS) at pH 7.4.  
All samples were filtered before analysis using a 0.2 µm Anotop 10 Whatman 
(Piscataway, NJ) 10 mm inorganic syringe filter.  A 384-well Corning (Corning, NY) 
polystyrene plate was used for these experiments.  Data were obtained in three 
consecutive acquisition periods, each 15 seconds in length, and averaged.  
Acquisitions were obtained every 2.5 °C over a temperature range of 10 °C to 67.5 °C 
with a ramping rate of 1 °C/min.  A constant nitrogen purge at 60 cc/min and 60 psi 
was performed to prevent condensation.  Average hydrodynamic radii and 
polydispersity indices were calculated using cumulant analysis.15 Two samples were 
prepared and analyzed for each set of solution conditions.  The resulting average and 
standard deviations were plotted.  Particle distribution was evaluated using a non-
negative least squares regularization method of analysis.16 A representative data set 
for each form of ATF5 was plotted.     
 
4.3 RESULTS 
4.3.1 Effects of C-terminal Truncation on ATF5 Structure 
Circular dichroism (CD) spectroscopy was performed to evaluate differences 
in secondary structure between the wild-type (WT) and the truncated mutant 
(V257STOP) forms of ATF5.  The mutant protein displays a CD absorption spectrum 
that is distinct from the WT form (Figure 4.1).  The WT possesses a double-minima 
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absorption pattern with negative peaks at 222 nm and 208 nm.  This pattern is 
indicative of α-helical protein structure.17 Given that the extended C-terminal portion 
of the protein was removed to make the V257STOP protein, one would expect that 
the remaining leucine zipper region would retain helicity, resulting in a proportional 
increase in overall helical signal.  In fact, the V257STOP mutant displays a single 
absorption minimum at 209 nm and a broad shoulder between 260 nm and 230 nm, 
which is not consistent with alpha-helical structure.  Negative absorption at 209 nm 
has been observed for proteins possessing β-structure.18 Additionally, it has been 
reported that certain types of β-bend can give negative absorption at 208 nm.19 The 
absorption observed between 260 nm and 230 nm could be attributed to β-turn 
structure, which has been demonstrated to display CD signal in this region.20  
Further experimental analysis of secondary structure was performed using 
Fourier transform infrared spectroscopy (FTIR) to better understand these structural 
differences.  Deconvolution of FTIR absorption in the Amide I region for the WT and 
V257STOP forms of ATF5 also indicates that the two proteins possess distinctly 
different secondary structure (Figures 4.2 and 4.3). The absorption peaks observed 
here are broader than those typically observed for a well-structured system.21 The 
data for both forms of ATF5 are suggestive of a dynamic or partially folded system.  
The WT form displays absorption peaks at 1621 cm-1, 1650 cm-1, 1676 cm-1 and 1688 
cm-1. The absorption band at 1621 cm-1 corresponds to β-sheet structure.12a, 22 The 
dominant absorption peak observed at 1650 cm-1 corresponds to α-helical 
structure.12a, 22 The absorption peak observed at 1676 cm-1 could represent β-sheet or 
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β-turn structure.12a, 22 Strong β-sheet absorption at low wavenumbers in the Amide I 
region (1620 cm-1 to 1639 cm-1) is often accompanied by weaker absorption at higher 
wavenumbers (1670 cm-1 to 1680 cm-1).21c, 23 It is likely, based upon the absorption 
observed at 1621 cm-1, that the peak at 1676 cm-1 primarily represents β-sheet 
structure. Lastly, the absorption peak at 1688 cm-1 is reflective of β-turn structure.12a, 
22  
The V257STOP mutant form of ATF5 displays broad absorption peaks at 
1644 cm-1 and 1682 cm-1.  While the fitting procedure resulted in the placement of 
two broad peaks for the mutant form, the second derivative data suggest the presence 
of two states, one of which may be α-helical (1650 cm-1) and the other unordered 
structure (1641 cm-1).12a, 22, 24 The broad absorption peak at 1682 cm-1 could represent 
β-sheet and/or β-turn structure.12a, 22 The absorption band observed at 1601 cm-1 
likely corresponds to side chain vibrations and is not predictive of secondary 
structure.25 
Additional studies were performed using two-dimensional NMR to compare 
chemical shift signal dispersion for the two forms of ATF5 (Figure 4.4).  The 1H-15N 
Heteronuclear Single Quantum Coherence (HSQC) experiment used here gives an 
indication of overall protein fold and structure based upon signal dispersion. This 
experiment can also provide general insight into protein dynamics, which are 
reflected in and often dictate peak shape and intensity.  Both forms of ATF5 display 
NH signals largely between 8.0 and 8.5 ppm on the 1H-axis (Figure 5). The signal 
observed between 6.5 ppm and 7.5 ppm arises from NH2 groups in the Asn and Gln 
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side chains, which typically have chemical shifts distinct from those of the NH groups 
in the amide backbone.  While some overlap in backbone signal is observed between 
the two forms of ATF5, their chemical shifts are largely distinct, which reaffirms the 
substantial differences in their overall structure and/or conformational dynamics.  A 
qualitative comparison of peak shape between the two spectra suggests that both 
forms of ATF5 possess well-defined structural regions as well as more 
conformationally labile regions.  This is illustrated by the presence of both sharp, 
circular cross-peaks that correspond to well-defined structure and broad, misshapen 
cross-peaks, which are indicative of conformational exchange. The NMR signal 
intensity is proportional to the concentration of protein and approximately reflects the 
amount of protein that is present in the monomeric/dimeric state. Large molecular 
weight species are not observed in the standard HSQC experiment, in this case self-
associated species composed of more than approximately 8-10 protomers. The signal 
to noise ratio observed in these experiments was 1.8-fold greater for the WT form 
than for the truncated mutant.  This suggests that roughly 45% of the mutant signal 
was lost due to protein aggregation or precipitation.  No visible precipitation was 
observed in the NMR sample tube, which indicates that the aggregate species must be 
soluble in nature. 
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Figure 4.1 CD absorption spectra of the WT (red) and the V256STOP mutant (blue) 
forms of ATF5 in 20 mM MES pH 6.0 at 4 °C.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2  Second derivative of FTIR spectra for the WT (red) and V257STOP 
mutant (blue) forms of ATF5 at 10 °C.  
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Figure 4.3 Deconvolution of the FTIR absorption spectra for the WT (A) and 
V257STOP mutant (B) forms of ATF5 at 10 °C. Absorption in the Amide I (1600 -
1700 cm-1) and Amide II (1500 -1600 cm-1) regions is plotted.  The black outline 
denotes the parent absorption spectrum.  The pink overlay indicates the fitted 
spectrum.  Individual absorption peaks in the Amide I region are color-coded 
according the structure they represent (blue = extended structure; red = alpha helix/ 
unordered; green = extended structure/ beta turn; purple = beta turn).  
 
A 
B 
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Figure 4.4 2D 1H-15N HSQC spectrum of 1 mM 15N-labeled ATF5 WT (red peaks) 
and V257STOP mutant (blue peaks) in 20 mM MES buffer, pH 6.0.  Peaks 
corresponding to NH2 side chains rather than NH backbone groups are boxed.
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4.3.2 Analysis of Change in Structure Observed During ATF5 Aggregation 
 In order to investigate the structural changes that accompany aggregate 
growth and development, FTIR analysis was employed.  This technique permits the 
analysis of sample both in solution and in the solid state, thereby allowing us to 
monitor structural changes that occur as the protein precipitates.  In these 
experiments, FTIR absorption was monitored for both forms of ATF5, each under 
reducing and non-reducing conditions, as a function of temperature (Figure 4.5).  The 
WT form begins to change structure between 10 °C and 25 °C.   This transition is 
characterized by a loss in α-helical structure at 1650 cm-1 and an increase in β-sheet 
structure at 1620 cm-1.  Increased absorption at ~1620 cm-1 is typically observed 
during protein aggregation and is indicative of intermolecular β-sheet structure.21a, 21c, 
23 In the presence of DTT, two isobestic points are observed for the WT melt (~1630 
cm-1 and 1670 cm-1).  This suggests that the loss of helical structure is directly linked 
to a gain in structure at lower and higher wavenumber.  In contrast, a more complex 
structural transition is observed for the WT form in the absence of DTT.  In this case, 
an initial loss of signal is observed between 10 °C and 25 °C at lower wavenumber, 
followed by a subsequent increase in β-sheet signal at 1620 cm-1. 
  Interestingly, the V257STOP mutant form of ATF5 does not change structure 
until the temperature rises above 40 °C.   A decrease in unordered absorption at 1644 
cm-1 and an increase in β-sheet absorption at 1620 cm-1 are then observed.  A loss in 
absorption at higher wavenumber (between 1670 cm-1 to 1700 cm-1) is also observed 
as a function of temperature.  This suggests a reduction in β-sheet or β-turn structure.  
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This loss continues until the temperature exceeds 70 °C, where a slight increase in 
absorption in this region is then observed.  The structural transitions observed for the 
V257STOP mutant are largely unaffected by DTT addition. 
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Figure 4.5 FTIR absorption in the Amide I region is shown for the WT and 
V257STOP forms both with and without 10 mM DTT at varying temperature.  Panels 
A and B show data collected on the WT form in the absence (A) and presence (B) of 
DTT. Panels C and D show data collected on the V257STOP mutant form in the 
absence (C) and presence (D) of DTT.  The data shown was collected at 10 °C (red), 
25 °C (blue), 40 °C (green), 55 °C (purple), 70 °C (light blue) and 90 °C (pink).    
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4.3.3 Effects of C-terminal Truncation on ATF5 Aggregation 
 
 Static light scattering (SLS) analysis was performed to compare the growth of 
thermally induced protein aggregates between the WT and V257STOP forms of 
ATF5.  In these experiments the average intensity of scattered light was measured in 
counts per second as a function of temperature under both reducing and non-reducing 
conditions (Figure 4.6). The onset of aggregation occurs much earlier for the WT 
form of ATF5 than for the V257STOP mutant.  In the presence of DTT, WT 
aggregation is characterized by a sharp increase in scattering intensity between 25 °C 
and 30 °C.  The scattering intensity eventually levels off and starts to decline at high 
temperature (between 70°C and 80 °C) due to the settling of large particles out of 
solution.  This was confirmed by visual inspection of samples following the melt.  In 
the absence of DTT, the WT onset of aggregation is shifted to higher temperature.  
An increase in scattering intensity is not observed until almost 40 °C.  Additionally, 
particulate growth appears to be more gradual under these conditions.   
Aggregation onset for the V257STOP mutant form of ATF5 is not observed 
until the temperature exceeds 50 °C.  Aggregation of this species is depicted by a 
gradual increase in scattering intensity observed between 60 °C and 70 °C, followed 
by a sharper increase in scattering intensity between 70 °C and 80 °C.  Unlike WT, 
the aggregation of this form of ATF5 is unaffected by the addition of DTT.  Further 
analysis was performed using dynamic light scattering (DLS) analysis to evaluate 
particle size distribution as a function of temperature.  
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Dynamic light scattering (DLS) uses autocorrelation analysis to measure the 
time-dependent fluctuations in light scattering intensity.  The autocorrelation function 
reflects particle diffusion in solution, which is directly related to particle size.  In 
these experiments the autocorrelation function was acquired at increasing 
temperatures for the two forms of ATF5 under both reducing and non-reducing 
solution conditions.  Cumulant analysis provided an average hydrodynamic radius 
(RH) value and polydispersity index for the particles in solution (Figure 4.7).15   
The WT form of ATF5 displays an average RH of 10 nm at 10 °C under both 
reducing and non-reducing solution conditions.  This average value is unchanged at 
low temperatures but begins to gradually increase in size between 25 °C and 30 °C.  
While this trend is the same for the WT protein under both reducing and non-reducing 
conditions, the average value becomes slightly larger for the reduced sample as a 
function of temperature.  In contrast, the V257STOP mutant form of ATF5 maintains 
an average RH of approximately 22 nm at nearly all temperatures measured.  A slight 
increase in average RH occurs for the V257STOP form as the temperature exceeds 60 
°C.  (Analysis above 65 °C was not performed, because the polystyrene plates used in 
these experiments cannot be used above this temperature.)  Again, there is no 
distinction between data collected under reducing and non-reducing solution 
conditions for the V257STOP mutant for ATF5.  
While this data provides useful information about trends associated with 
increasing temperature, the cumulant analysis provides an average RH value.  The 
polydispersity index reported with the average value provides an estimation of 
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distribution about the mean.  The polydispersity values reported for both the WT and 
V257STOP systems suggest multimodal sample populations (Figure 4.8).  
Additionally, the average values reported here are much larger than what would be 
expected for ATF5 monomer or dimer.  For example an IgG mononclonal antibody 
with an estimated molecular weight of 150 kDa typically displays an average 
hydrodynamic radius of approximately 5 nm to 8 nm26.  This suggests that self-
associated protein species are present in both the WT and V257STOP samples.  
Solution polydispersity decreases for both forms of ATF5 as particle size increases 
(Figure 8).  This could be related to the development of micron-size protein 
aggregates that exceed the range of DLS detection (approximately 0.5 nm to 1 µm).  
As protein precipitates from solution, the polydispersity of the remaining soluble 
species may be lowered.  
Regularization analysis is an alternative method for analyzing DLS data that 
makes no assumptions about sample homogeneity and permits characterization of 
multimodal sample populations.16 This analysis was performed on the dynamic light 
scattering data collected for both forms of ATF5 between 10 °C and 65 °C.  The data 
is plotted as a distribution illustrating the relative intensity of light scattered as a 
function of particle size in solution (Figure 4.9).  The data for both forms of ATF5 
indicate heterogeneous, multimodal sample populations.  The WT sample contains 
two sample populations.  A smaller species ranging from approximately 2 nm to 4 nm 
in radii that likely represents monomeric or dimeric protein, and a larger population 
that ranges from 8 nm to 35 nm in size and consists of aggregated protein species. 
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The V257STOP sample also contains two sample populations. A smaller species 
ranging again from approximately 2 nm to 4 nm in radii that reflects monomeric or 
dimeric protein and a larger population ranging from 10 nm to 70 nm in size that is 
consistent with aggregated species.   
The range in size observed for protein monomer/dimer is consistent with the 
NMR data, which indicates a partially folded and highly dynamic system.  The range 
observed for the aggregated species indicates the existence of particles of varying 
sizes.  Interestingly, the V257STOP mutant form consistently displays a much 
broader size range of aggregated protein than the WT form.  Moreover, this 
distribution remains relatively constant across the temperatures measured.  This in 
contrast to the WT, whose aggregated population steadily increases in size as a 
function of temperature.  This suggests that aggregation of the WT form occurs 
through the growth or increase in size of soluble protein aggregates in the 10 to 35 
nanometer size range. 
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Figure 4.6 SLS analysis of the WT and V257STOP truncated forms of ATF5 in both 
the absence and presence of 10 mM DTT. The intensity of scattered light is plotted as 
a function of temperature.  Data for the WT form in the absence and presence of DTT 
is illustrated in red and purple, respectively.  Data for the V257STOP mutant in the 
absence and presence DTT is illustrated in blue and green, respectively. 
 
 
 
 
 
Figure 4.7 DLS analysis of the WT and V257STOP truncated forms of ATF5 in both 
the absence and presence of 10 mM DTT.   The average hydrodynamic radii are 
plotted as a function of temperature.  Data for the WT form in the absence and 
presence of DTT is illustrated in red and purple, respectively.  Data for the 
V257STOP mutant in the absence and presence DTT is illustrated in blue and green, 
respectively. 
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Figure 4.8 DLS analysis of the WT and V257STOP truncated forms of ATF5 in both 
the absence and presence of 10 mM DTT.   The polydispersity index is plotted as a 
function of temperature.  Data for the WT form in the absence and presence of DTT 
is illustrated in red and purple, respectively.  Data for the V257STOP mutant in the 
absence and presence DTT is illustrated in blue and green, respectively. 
 
 
106 
106 
 
 
 
Figure 4.9 DLS distribution data for the (A) WT and (B) V257STOP truncated form 
of ATF5. The percent intensity of scattered light is displayed as a function of 
hydrodynamic radius.  
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4.4 Discussion 
In this report we compare the structure and aggregation of the wild-type (WT) 
form of ATF5 with a truncated mutant form that lacks the valine zipper region 
(V257STOP).  The truncated ATF5 displays a distinctly different structure than the 
WT form.  Removal of the valine zipper region results in a loss of α-helical structure.  
This is interesting because the leucine zipper region of ATF5 is the region with the 
highest propensity to adopt α-helical structure, whereas the valine zipper region is 
predicted to be disordered but have beta propensity.11 Based on this information, one 
would expect that removal of the valine zipper region would result in an increased 
overall helical structure for the mutant.  Interestingly, the opposite effect is observed.  
This indicates that the valine zipper region is important for maintaining the α-helical 
structure of the adjacent helical region. If as predicted, the central leucine zipper 
region is the most structured region of ATF5, then the valine zipper region must help 
stabilize this helical structure. It is not clear whether structural stabilization is 
accomplished through backbone or side-chain interactions or both. 
 The dynamic light scattering data indicate that both forms of ATF5 tend to 
self-associate at low temperature (10 °C).  It is difficult to quantify the extent of self-
association, because both systems are highly dynamic and heterogeneous.  However, 
based upon the NMR signal achieved using millimolar concentrations of protein, a 
large percentage of these samples must be present in their low molecular weight 
monomeric/dimeric form in order to be observed on the ΝΜR timescale.27 The 
structural data collected using CD and FTIR reflect the structure of both free and self-
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associated protein species. As such, it is likely that the helical signal observed for the 
WT form of ATF5 is largely reflective of the base protomer structure and the β-
structure observed reflects the presence of self-associated protein species.  Stable beta 
structure would result in NH chemical shifts appearing further downfield, above 8.5 
ppm, and no such signal is observed in the spectra. 
The structural data collected on the mutant form of ATF5 indicate that the 
protein possesses β-sheet and β-turn structure.  However, the data also suggest that 
the system contains non-standard structural features.  Again, because ATF5 self-
association occurs at low temperature, the CD and FTIR data may reflect signal from 
both monomeric or dimeric species and larger soluble aggregates.  The complexity of 
this system precludes clear delineation of the structure of the V257STOP mutant.  
Extensive higher resolution studies using multi-dimensional NMR will be required to 
describe this system in further detail. 
Thioflavin T fluorescence was measured in the presence of both forms of 
ATF5 as a function of temperature.  Thioflavin T is a fluorescent dye commonly used 
for the detection of amyloid fibrils.28 Interestingly, the mutant form of ATF5 was able 
to induce Thioflavin T fluorescence, but the WT did not induce fluorescence.  The 
emission intensity at 480 nm for the mutant was 710,813 counts/second at 10 °C and 
the emission intensity for the WT at the same temperature was 875 counts/second.  
Despite the presence of aggregates in both samples a 1000-fold difference in emission 
intensity was observed.  These data indicate that the initial aggregated or self-
associated state of the V257STOP mutant possesses a structure or conformation that 
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is able to bind and induce Thioflavin T fluorescence.  Given that Thioflavin T 
fluorescence is typically observed in the presence of fibrillar or amyloid aggregates, 
this suggests that the initial aggregated state of the mutant protein possesses structural 
features that are similar to those present in amyloid fibrils.28 The fact that the WT 
form of ATF5 does not induce Thioflavin T fluorescence indicates that a structural 
difference exists between the soluble aggregated forms of the two proteins.   
The FTIR data indicate that the final aggregated states of the two forms of 
ATF5 are structurally similar.  The increased FTIR absorption signal at 1620 cm-1 is 
reflective of intermolecular β-structure and has been observed for numerous 
aggregated protein species.21a, 21c, 23, 25 This suggests that while the pathway or 
mechanism leading to the formation of the final state may differ between proteins, the 
structure of the final state is sequence independent.21a, 21c, 23, 25 
 It appears that the WT form of ATF5 protein possesses a conformation that 
readily permits intermolecular β-sheet addition or elongation.  Our initial hypothesis 
was that solution exposure of the valine zipper region facilitated protein self-
association through the initiation of intermolecular β-structure.  Therefore, under 
reducing conditions, where the valine zipper region is more exposed, protein 
aggregation occurs more readily.  Our data show that upon removal of the valine 
zipper region, the bZIP domain still self-associates, but these soluble structured 
aggregates are thermally-stable thus reducing further aggregate growth.  Moreover, 
no difference in aggregation is observed between the reduced and non-reduced forms 
of the ATF5 mutant.  It appears that removal of the valine zipper region changes the 
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conformation of the alpha-helical region such that intermolecular disulfide bond 
formation is no longer a determining factor in aggregate formation, structure or 
thermal stability. 
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CHAPTER 5 
 CONCLUSIONS AND FUTURE WORK 
 
5.1 CONCLUSIONS  
 Intermolecular disulfide bond formation of the basic leucine zipper (bZIP) 
domain of Activating Transcription Factor 5 (ATF5) reduces the size of thermally 
induced protein aggregates through the retention of alpha-helical structure.  Removal 
of the C-terminal valine zipper region results in a loss of alpha-helical structure and a 
change in the mechanism of protein self-association.  The ATF5 protein displays 
improved thermal stability with regard to aggregate growth in the absence of the 
valine zipper region, despite an increased tendency to self-associate at lower 
temperatures. 
 
5.2 FUTURE WORK 
5.2.1 Aggregation Kinetics 
 Kinetic analyses are often employed when studying protein 
aggregation and can provide valuable mechanistic information.  While various 
aggregation models have been reported in the literature, they can generally be 
classified into the following categories:  unfolding-limited, aggregation-limited and 
nucleation/growth-limited.1 Unfolding-limited kinetics describe a system in which the 
unfolding of the protein is slow and rate-limiting compared to aggregation.1b, c This 
system will display true first-order kinetics.  In all other cases, where refolding of the 
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protein is fast compared to aggregate formation, a folding equilibrium will be 
maintained over the course of the experiment.1b, c In an aggregation-limited system 
the simplest model assumes that dimer formation is rate-limiting and equivalent to the 
rate of subsequent growth.1b, c This system will display second-order kinetics and the 
observed rate constant (kobs) will be dependent upon the initial protein concentration 
(C0).  Lastly, a nucleation/growth driven system describes the case where protein self-
association is thermodynamically unfavorable up to a certain oligomerization state 
and growth occurs only by aggregate elongation or polymerization.1b, c  (Aggregate-
aggregate association is negligible in this case.)  This system will display first-order 
kinetics because nucleation is finished after only a small fraction of monomer is lost.  
The rate constant will also depend upon C0.  In cases where aggregate-aggregate 
association is observed, the overall aggregate concentration will decline in proportion 
with the rate of new aggregate formation.1b, c Given the simplest case provided above, 
where dimer formation is rate-limiting, the system would display second-order 
kinetics.  
Some degree of ambiguity can clearly arise in discerning between the general 
aggregation mechanisms described above.  Certainly, reaction order alone would not 
be sufficient to assign mechanism.  Evaluating the dependence of kobs on C0 would 
also be important.  Furthermore, an initial monomeric state would be preferred to 
perform these analyses.  A more complicated starting point could limit the amount of 
information that could be obtained.  The Activating Transcription Factor 5 (ATF5) 
system presented herein would contain monomeric protein, covalent dimer and 
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soluble aggregates at time zero.  The interpretation of kinetic data from this system 
could be quite complex given the initial conditions.  Moreover, given that nucleation 
has already occurred in this system, analysis might be limited to the evaluation of 
growth kinetics.     
An important consideration when performing kinetic analysis is the 
methodology used to detect and quantitate aggregation.1b, c Often direct detection is 
performed using size exclusion chromatography (SEC).1b, c Unfortunately, SEC is not 
a viable option for the analysis of ATF5 aggregation, because the protein adsorbs to 
the stationary phase of the column.  Other direct methods of analysis include native 
PAGE analysis and analytical ultracentrifugation (AUC).1b, c A disadvantage of native 
PAGE analysis is that it is only a semi-quantitative method.  Additionally, AUC 
analysis typically requires substantial user training and can be quite time-consuming 
in comparison to SEC.   
Certainly indirect methods of analysis are available and often used.1b, c 
Solution turbidity can be easily monitored over time, but detects only insoluble 
aggregates Alternatively, dynamic light scattering (DLS) analysis will monitor the 
development of soluble aggregates, but not larger insoluble species.  Static light 
scattering (SLS) is another viable option for quantitative detection, but would require 
substantial experimental modification from the current set-up to accommodate multi-
angle detection.  Spectroscopic analysis including fluorescence, circular dichroism 
(CD) and Fuorier transform infrared spectroscopy (FTIR) have also been used to 
monitor structural changes that reflect aggregate formation over time.1b, c However, 
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the complete lack of tryptophan residues in ATF5 limits the usefulness of a 
fluorescence assay.  Furthermore, the complexity of the ATF5 solution, which 
contains both monomer/dimer and aggregated species, limits the unambiguous 
assignment of specific spectral features for this purpose.    
5.2.2 High-Resolution Structural Analysis using Nuclear Magnetic Resonance 
Spectroscopy (NMR) 
 NMR analysis could be used to obtain more detailed structural information 
about the WT and V257STOP forms of ATF5.2 This analysis would require the 
execution of three-dimensional NMR experiments that would facilitate the 
assignment of spectral peaks to specific amino acid residues.  However, this 
assignment may prove difficult given the complex nature of the two-dimensional 1H-
15N heteronuclear single quantum coherence (HSQC) spectra already obtained.  
Typically, the time-consuming process of NMR peak assignment is not undertaken 
until a well-behaved protein system can be obtained.  This means that peak overlap is 
minimal and protein conformational exchange is limited.  In the case of ATF5, there 
are numerous overlapping peaks and clear evidence of conformational exchange.  If 
peak assignments can be obtained, then there is the potential to obtain higher-
resolution information about ATF5 structure.  Moreover, protein dynamics and 
structural changes associated with increasing temperature might be investigated in 
more detail.  
5.2.3 Additional Particle Characterization  
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 While the static light scattering (SLS) and dynamic light scattering (DLS) 
analyses performed in these studies provide useful information about particle growth 
associated with ATF5 aggregation, the data still lacks the detail and quantitation 
required to fully characterize this system.  Complementary techniques are available 
that would provide additional information about the aggregation of ATF5.  Micro-
Flow Imaging (Brightwell Technologies Inc.) uses digital microscopy and micro-
fluidics to image particles in solution.3 This technique provides information about the 
number, size and shape of particles within the micron size range (approximately 1 µm 
to 300 µm).  This information would complement that obtained using DLS, which 
detects particles in the nanometer size range (approximately 1 nm to 1000 nm).  It 
would permit a quantitative comparison of the size and morphology of insoluble 
protein aggregates between the WT and V257STOP forms of ATF5. 
Another new technology that is used for particle analysis is NanoSight 
(NanoSight Ltd.), which uses optical microscopy to track the diffusion of 
nanoparticles in solution.4 In this method each particle is measured separately, which 
permits better resolution and quantitation of different sized particles in solution than 
that obtained using DLS.  The size range for nanoparticle detection using NanoSight 
is approximately 30 nm to 1000 nm for protein aggregates (depending on refractive 
index).  Smaller species (below 30 nm) that can be detected using DLS will not be 
observed using this method.  However, NanoSight analysis could provide a more 
quantitative comparison of the size and distribution of the soluble aggregates between 
the WT and V257STOP forms of ATF5. 
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5.2.4 Single Point Mutations in the Valine Zipper Region  
 Further investigation of the role of the valine zipper region in facilitating 
ATF5 aggregation could be performed by introducing point mutations into this C-
terminal region.  For example, we have suggested that the inherent propensity of 
valine residues to adopt beta conformation versus α-helical structure may explain the 
more facile aggregation of ATF5 observed with the valine zipper region intact.5 This 
could be evaluated by mutating the individual valine residues in this region (V257, 
V264 and V271) to leucine, which has a lower propensity to adopt β-structure.  In 
fact, mutagenesis has already been performed on the ATF5 cDNA in the pET-42b 
expression vector to create the following constructs toward this end: V257L, V264L 
and V271L.  Additionally, the double mutant V257L/V264L and the triple mutant 
V257L/V264L/V271L have also been made.  Preliminary data from the initial 
purification of these mutant forms of ATF5 indicates that their solubility following 
cell lysis differs from the WT form.  It is likely that modified purification schemes 
will be required for mutant protein isolation.  
5.2.5 Agitation-Induced Protein Aggregation Studies  
 Increased exposure to an air-water interface is known to induce protein 
aggregation.6 It is believed that proteins can partially unfold at this interface and then 
more readily self-associate in solution.  Sample agitation is one way in which 
increased exposure to this interface can occur.6 Agitation studies are commonly 
employed in the biopharmaceutical industry to evaluate product stability.  It is likely 
that the mechanism of protein aggregation is influenced by the type of stress applied 
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during a stability study.  The development of thermally induced protein aggregates 
can therefore proceed through a different mechanism than that observed for agitation-
induced aggregation.  Therefore, studies comparing the aggregation of the WT and 
the V257STOP forms of ATF5 could be extended to evaluate the effects of agitation 
on ATF5 aggregation.     
5.2.6 Impact of Excipient Addition on ATF5 Aggregation 
 Excipients are solution additives that are commonly used to improve protein 
stability.7 Although there are existing theories about how these additives function to 
stabilize proteins, in many cases the exact mechanisms remain unclear.  Given that 
the WT and V257STOP forms possess different structure and self-associate 
differently, it would be interesting to compare the effects of excipient addition on 
these two systems.  Preliminary screening was performed using different types of 
excipients to evaluate their impact on ATF5 aggregation.  The data indicate that 
sucrose, arginine and polysorbate 20 all have obvious, but unique effects on ATF5 
aggregation.  A more detailed analysis is currently underway to compare the effects 
of these three excipients at varying concentration on the stability of the WT and 
V257STOP forms of ATF5.    
122 
122 
5.3 REFERENCES 
1. (a) Morris, A. M.; Watzky, M. A.; Finke, R. G., Protein aggregation kinetics, 
mechanism, and curve-fitting: a review of the literature. Biochim Biophys Acta 2009, 
1794 (3), 375-97; (b) Roberts, C. J., Non-native protein aggregation kinetics. 
Biotechnol Bioeng 2007, 98 (5), 927-38; (c) Weiss, W. F. t.; Young, T. M.; Roberts, 
C. J., Principles, approaches, and challenges for predicting protein aggregation rates 
and shelf life. J Pharm Sci 2009, 98 (4), 1246-77. 
2. Wuthrich, K., NMR studies of structure and function of biological 
macromolecules. Biosci Rep 2003, 23 (4), 119-68. 
3. Wuchner, K.; Buchler, J.; Spycher, R.; Dalmonte, P.; Volkin, D. B., 
Development of a microflow digital imaging assay to characterize protein particulates 
during storage of a high concentration IgG1 monoclonal antibody formulation. J 
Pharm Sci 2010, 99 (8), 3343-61. 
4. Filipe, V.; Hawe, A.; Jiskoot, W., Critical evaluation of Nanoparticle Tracking 
Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein 
aggregates. Pharm Res 2010, 27 (5), 796-810. 
5. Ciaccio, N. A.; Laurence, J. S., Effects of disulfide bond formation and 
protein helicity on the aggregation of activating transcription factor 5. Mol Pharm 
2009, 6 (4), 1205-15. 
6. (a) Kiese, S.; Papppenberger, A.; Friess, W.; Mahler, H. C., Shaken, not 
stirred: mechanical stress testing of an IgG1 antibody. J Pharm Sci 2008, 97 (10), 
4347-66; (b) Serno, T.; Carpenter, J. F.; Randolph, T. W.; Winter, G., Inhibition of 
agitation-induced aggregation of an IgG-antibody by hydroxypropyl-beta-
cyclodextrin. J Pharm Sci 2010, 99 (3), 1193-206; (c) Sicorello, A.; Torrassa, S.; 
Soldi, G.; Gianni, S.; Travaglini-Allocatelli, C.; Taddei, N.; Relini, A.; Chiti, F., 
Agitation and high ionic strength induce amyloidogenesis of a folded PDZ domain in 
native conditions. Biophys J 2009, 96 (6), 2289-98. 
7. (a) Hamada, H.; Arakawa, T.; Shiraki, K., Effect of additives on protein 
aggregation. Curr Pharm Biotechnol 2009, 10 (4), 400-7; (b) Manning, M. C.; Patel, 
K.; Borchardt, R. T., Stability of protein pharmaceuticals. Pharm Res 1989, 6 (11), 
903-18. 
 
 
 
  
 
